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The human circulatory system is re-
sponsible for delivering food, oxygen, and
other needed substances to all cells in
all parts of the body while taking away
waste products. The circulatory sys-
tem is also known as the cardiovascu-
lar system, from the Greek word kar-
dia, meaning ”heart,” and the Latin vas-
culum, meaning ”small vessel.” The ba-
sic components of the cardiovascular sys-
tem are the heart, the blood vessels, and
the blood. As blood circulates around
the body, it picks up oxygen from the
lungs, nutrients from the small intestine,
and hormones from the endocrine glands,
and delivers these to the cells. Blood
then picks up carbon dioxide and cellu-
lar wastes from cells and delivers these
to the lungs and kidneys, where they are
excreted (Stranding, 2009).
1.1 Histomorphology and classifi-
cation of blood vessels
The blood vessels of the body (arteries,
capillaries, and veins) make up a closed
system of tubes that carry blood from
the heart to tissues all over the body and
then back to the heart. Arteries carry
blood away from the heart, while veins
carry blood toward the heart. Large ar-
teries leave the heart and branch into
smaller ones that reach out to various
parts of the body. These divide still fur-
ther into smaller vessels called arterioles
that penetrate the body tissues. Within
the tissues, the arterioles branch into a
network of microscopic capillaries. Sub-
stances move in and out of the capillary
walls as the blood exchanges materials
with the cells. Before leaving the tissues,
capillaries unite into venules, which are
small veins. The venules merge to form
larger and larger veins that eventually re-
turn blood to the heart.
The walls of arteries, veins, and cap-
illaries differ in structure. In all three,
the vessel wall surrounds a hollow cen-
ter through which the blood flows. The
walls of both arteries and veins are com-
posed of three coats, but they differ in
thickness. The inner and middle coats of
arteries are thicker than those of veins.
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This makes arteries more elastic and ca-
pable of expanding when blood surges
through them from the beating heart.
The walls of veins are more flexible than
artery walls. This allows skeletal mus-
cles to contract against them, squeezing
the blood along as it returns to the heart.
One-way valves in the walls of veins keep
blood flowing in one direction. The walls
of capillaries are only one cell thick. Of
all the blood vessels, only capillaries have
walls thin enough to allow the exchange
of materials between cells and the blood
(Fig. 1.1).
Arteries and veins are classified
mainly by their anatomic position and di-
vided in 3 main classes: Resistance ves-
sels (arteries and arterioles); Exchange
vessels (capillaries, sinusoid and venules)
and at the end capacity vessels (veins)
(Stranding, 2009).
All arteries show a common pattern of
Figure 1.1. Representative scheme of cardiovascular system.
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organization and are made up of similar
material, thought the proportions vary in
different parts of the circulation. The ar-
terial wall is well organized connective
tissue structures composed of cells and
matrix fibers arranged in three tunicae:
the intima, the media and the adventitia
(Fig. 1.2).
Tunica intima
The innermost subluminal layer consists
of endothelium and a variable quantity
of underlying cells and matrix elements,
constituting, from the lumen to the outer
part of the arterial wall: the basement
membrane, the sub-endothelial layer and
the internal elastic lamina. A continu-
ous monolayer of polygonal flat cells (0,3
to 0,5 µm), the endothelium, lines the
luminal surface of all arteries. The en-
dothelium layer extends as a continuous
lining right through the circulation, cov-
ering all the surfaces which come in con-
tact with the blood-arteries, capillaries,
veins, heart valves and endocardial sur-
faces (Le´vy et al, 1999).
Endothelium
The endothelium is continuously sub-
mitted to shearing forces related to blood
flow and exposed to circulating cells and
Figure 1.2. The vascular wall architecture.
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plasma components In relation to shear
stress, endothelial cells tends to be elon-
gated (± 100 µm) in the direction of
blood flow, particularly where the lat-
ter is rapid, laminar and unidirectional.
Where flow is slow, complex, turbulent,
or nearly stagnant, the endothelial cells
are less distinctly elongated or oriented.
In vitro experiments confirmed that cul-
tured endothelial cells are oriented and
elongated in the direction of the shear
stresses (Levesque et al, 1985). The lumi-
nal surface of the endothelial cells, largely
smooth and regular (Clark et al, 1976),
is covered by a glycoprotein coat consti-
tuting the glycocalix responsible of the
anti-thrombogenic properties of endothe-
lial surface. In some arteries where the
endothelial layer is submitted to high
shear stress levels, as in the angle of
bifurcations, the rate of renewal of en-
dothelial cells is higher and can reach
10 cells over 100 per day. The endothe-
lial cell ECs have multiple functions such
as a permeability barrier (Pappenheimer,
1953), regulation of hemostasis (Aird,
2001), leukocyte recruitment and hom-
ing (Butcher, 1991), and vascular wall
tone control (Moncada et al, 1991). Fur-
thermore, the wide diversity of antigens
found on the endothelial surface may ex-
plain the susceptibility of the cell to im-
munologic injury. Therefore, it appears
that the endothelial cell not only serves
a multiplicity of primary vascular func-
tions but it is also a highly diversified
synthetic cell, the function of which may
markedly influence the response of vessels
to a number of agent or stimuli (Le´vy et
al, 1999).
Tunica media
The media is constituted principally
of smooth muscle cells (SMCs), elastic
fibers, and collagen fibers separated by
the internal and external elastic laminae.
Arteries are classified as elastic or muscu-
lar types according to the relative propor-
tions of these cellular and fibrous compo-
nents found in the media (Wolinsky et al,
1967). In elastic arteries, matrix fibers,
in the form of well defined elastic lamel-
lae and collagen bundles, are abundant
and prominent in the media. The con-
ducting vessels of relatively large diame-
ter in close proximity to the heart (such
as aorta, brachiocephalic trunk, iliac and
the main pulmonary arteries) are exam-
ples of elastic arteries. The media of mus-
cular arteries contains fewer connective
tissue fibers than that of elastic arteries;
smooth muscle cells being the predomi-
nant component. The predominant mus-
cular composition of these vessels cor-
responds to greater capacity to change
diameter actively under the influence of
neurohumoral stimulation. The relative
proportions of elastin and collagen in the
aortic media change with distance from
the heart and also vary from vessels to
vessels. The thoracic aorta contains a
greater quantity of elastin than collagen,
whereas the abdominal aorta has more
collagen than elastin. Yet, the sum of the
collagen and elastin along the aorta does
not change with distance from the heart.
The role of the medial tunica is both to
bestow elasticity to the vessel (in big cal-
iber arteries there are abundant elastic
fibers and few contractive ones) and con-
traction (in muscular arteries there are
13
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more muscular than elastic components)
(Le´vy et al, 1999).
Tunica adventitia
The external elastic lamina is the inner
limit of the adventitia; in contrast, the
outer limit of the adventitia is often dif-
ficult to define: it is usually contiguous
with the perivascular connective tissue.
The aorta has relatively slight adventitial
condensation of fibrous connective tissue
whereas the adventitia of the large mus-
cular arteries consists of prominent elas-
tic and collagen fibers in well-organized
layers. In these locations, adventitia may
be thicker than the media. However,
adventitial cells are sparse and mainly
fibroblasts; the adventitia also contains
few thick elastic fibers. The adventitia
contains vasa vasorum and nerves, the
former providing nutrition to the adven-
titia and media; the latter contributing to
the regulation of medial smooth muscle
function. Vasa vasorum exist only in ar-
teries with diameter larger than 200µm;
the outer part of the media is irrigated by
the vasa vasorum. Thus, the oxygen and
metabolites supply of the smooth mus-
cle cells are provided both from the lu-
minal blood flow (for the inner part of
the media) and from the vasa vasorum
(for the outer layers of the media). A
lymphatic network contained in the ad-
ventitia collects the proteins, ions, sol-
uble substances and water coming from
the blood and transported through the
vessel wall.
Figure 1.3. Anatomical distribution of AA, TA and FA.
14
1 – The Vascular System
1.2 Anatomy of aortic arch, tho-
racic aorta and femoral artery
Aorta and Aortic arch
The aorta is an elastic artery, and as
such is quite distensible; it consists of a
heterogeneous mixture of smooth mus-
cle, nerves, intimal cells, endothelial cells,
fibroblast-like cells, and a complex ex-
tracellular matrix. The thickness of the
aorta encourages an extensive network
of tiny blood vessels called vasa vaso-
rum which feed the layers of the aorta.
The aortic arch (AA) contains barorecep-
tors and chemoreceptors which relay in-
formation concerning blood pressure and
blood pH and carbon dioxide levels to the
medulla oblongata of the brain. The arch
of the aorta connects the ascending aorta
with the descending aorta; it begins at
the level of the upper border of the sec-
ond sternocostal articulation of the right
side, and runs at first upward, backward,
and to the left in front of the trachea; it is
then directed backward on the left side of
the trachea and finally passes downward
on the left side of the body of the fourth
thoracic vertebra, at the lower border of
which it becomes continuous with the de-
scending aorta. Its upper border is usu-
ally about 2.5 cm. below the superior
border to the manubrium sterni. Three
elastic arteries originate along the aortic
arch: brachiocefalic artery, left common
carotid artery, left subclavian artery. It
lies within the mediastinum. (Martini,
2007; Stranding, 2009) (Fig. 1.3).
Thoracic aorta
The thoracic aorta (TA) is contained
in the posterior mediastinal cavity. It be-
gins at the lower border of the fourth tho-
racic vertebra where it is continuous with
the aortic arch, and ends in front of the
lower border of the twelfth thoracic verte-
bra, at the aortic hiatus in the diaphragm
where it becomes the abdominal aorta.
It travels within the mediastinum , on
the posterior thoracic wall, slightly to the
left of the vertebral column. This ves-
sel supplies blood to branches that ser-
vice the tissues and organs of the me-
diastinum, the muscles of the chest and
the diaphragm, and the thoracic spinal
cord (Martini, 2007; Stranding, 2009)
(Fig. 1.3).
Femoral artery
The femoral artery (FA) is a general
term comprising a few large muscular ar-
teries in the thigh. The femoral artery
is divided into three parts: the com-
mon femoral artery which divides into
the deep femoral artery, which provides
blood to the thigh, and the superficial
femoral artery, which provides blood to
the arteries that circulate the knee and
foot. The femoral arteries receive blood
through the external iliac artery. This
connection occurs at the femoral trian-
gle behind the inguinal ligament which is
usually near the head of the femur bone.
That proximal section of the femoral
artery, known specifically as the common
femoral artery, leaves the femoral trian-
gle through an apex beneath the sarto-
rius muscle. It then divides into a deep
and superficial femoral. The deep ves-
sel is more commonly known as the Pro-
funda FA which provides blood to the
15
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thigh. The other branch is the super-
ficial femoral artery; it connects to the
popliteal artery at the opening of adduc-
tor magnus or hunter’s canal towards the
end of the femur (Martini, 2007; Strand-
ing, 2009) (Fig. 1.3).
1.3 Embryological origin of the
Vascular Wall Cells (VWCs)
Yolk sac hemangioblast
According to classic embryology stud-
ies the first ECs in the gastrulating em-
bryo originate from the lateral and pos-
terior mesoderm. Newly-formed lateral
and posterior mesodermal cells migrate
toward the yolk sac, where they will
differentiate to ECs and hematopoietic
cells (HCs) of the blood islands (Mur-
ray, 1932). The cells constituting the
outer layer of the blood islands assume
a spindled morphology and then differ-
entiate into ECs, while the vast majority
of the inner cells progressively lose their
intercellular attachments as they differ-
entiate into hematopoietic cells (Shep-
ard et al, 2000). The intimate anatomic
and chronological association existing be-
tween blood and vascular development
suggests that ECs and hematopoietic
cells share a bipotent mesodermal ances-
tor called hemangioblast (Murray, 1932;
Sabin, 1920). A recent enhancement of
the hemangioblast concept, further es-
tablishing the close embryonal relation-
ship between the vascular system and
the hematopoietic system comes from re-
cent studies supporting the existence of
a hemogenic endothelium in the dorsal
aorta, a cell committed to the endothelial
lineage, but capable, in the mean time, to
give rise to hematopoietic cells. Based
on the expression of transcription fac-
tor Runx1 that regulates the definitive
hematopoiesis, mice development stud-
ies demonstrate that hemopoietic en-
dothelial cells (Runx1+) represent a sub-
population of the yolk sac endothelium
and could also be found in the floor of
the dorsal aorta within the aorta-gonad-
mesonephros region. The hematopoietic
region was so called hemogenic endothe-
lium and generates definitive hematopoi-
etic cells including hematopoietic stem
cells (Ribatti, 2008; Bollerot et al, 2005).
Tavian et al. in 2001 confirmed this hy-
pothesis in chicken and human embryos
as well (Tavian et al, 2001). Unlike what
happens in the yolk sac where ECs and
HCs appear simultaneously, the aorta is
formed at least 1 day before the emer-
gence of the hematopoietic clusters, sug-
gesting the existence of an aorta-specific
type of hemangioblast (Bollerot et al,
2005).
The growth of ECs determines conflu-
ence of blood islands to form small ves-
sels (Murray, 1932) a sort of primitive
vascular labyrinth of small capillaries, a
process known as vasculogenesis. Inter-
estingly, already at this stage capillaries
have acquired an arterial and venous cell
fate, indicating that vascular-cell speci-
fication is genetically programmed and
not only determined by haemodynamic
force. During the angiogenesis phase,
the vascular plexus progressively expands
by means of vessel sprouting and remod-
els into a highly organized and stereo-
typed vascular network of larger vessels
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ramifying into smaller ones. Nascent
ECs channels become covered by peri-
cytes (PCs) and SMCs, which provide
strength and allow regulation of vessel
perfusion, a process termed arteriogene-
sis (Carmeliet, 2005) (Fig. 1.4).
Smooth muscle progenitors
The embryological origin of vascular
SMCs is more complex than thought be-
fore. According to classic studies the vas-
cular SMCs arise from the portion of the
yolk sac mesoderm which is closely as-
sociated with differentiating endothelium
(splancnic mesoderm). However, several
studies have focused on the heterogene-
ity of normal adult SMCs a characteristic
which is further enhanced in the course of
vascular diseases (Hao et al, 2003); these
functional and structural differences were
believed to be a consequence of the in-
trinsic cell plasticity through which a sin-
gle SMC can switch its contractile phe-
notype into a synthetic one in response
to chemical and mechanical variations
in the local microenvironment; however
recent studies of lineage mapping and
specific mutagenesis in vertebrate mod-
els suggest that the cause of these dif-
ferent response abilities relies on the dif-
ferent SMC embryological origin (Ma-
jesky, 2003). Indeed, different vessels, or
even different segments of the same ves-
sel, are composed of distinct SMC pop-
ulations that arise from specific sources
of smooth muscle progenitors (Majesky,
Figure 1.4. Formation of blood vessels.
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2007). In 1975, Le Lievre and Le Douarin
first reported a detailed fate maps that
revealed a neural crest origin for vascu-
lar SMCs. From the original location,
progenitors migrate and accumulate in
the walls of pharyngeal arch arteries, be-
coming closely associated with ECs of
the branchial arch arteries, and differ-
entiate into vascular SMCs (LeLievre et
al, 1975). A subset of these cells con-
tinues to migrate into the cardiac out-
flow tract where they mediate septation
of the aorta and pulmonary trunk (Kirby
et al, 1983). A genetic approach that
used a Wnt1-Cre transgenic line crossed
with a floxed stop Rosa26 reporter line
(R26R) confirmed the important role of
neural crest cells in mammalian vascu-
lar development by following the activa-
tion of a LacZ reporter gene. This study
showed that murine neural crest con-
tributes SMCs to the ascending and arch
portions of the aorta, the ductus arterio-
sus, the innominate and right subclavian
Figure 1.5. Different embryological origin of SMCs (from Pacilli et al, 2009).
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arteries, as well as the right and left com-
mon carotid arteries while does not con-
tributes SMCs to the descending thoracic
aorta, abdominal aorta, coronary arter-
ies, pulmonary arteries, left subclavian
artery and distal portions of the inter-
nal carotid arteries (Jiang et al, 2000).
The development of coronary vessels, in
fact, is separate and distinct from that
of the systemic vasculature and coro-
nary SMCs derive from progenitors lo-
cated in the proepicardium (Wada et al,
2003; Gittemberger-de Groot et al, 1998).
The SMCs of the descending aorta, in-
stead, derive from somites. The embry-
onal aorta develops in close proximity to
the somites and xenograft and genetic
studies show a segmental origin of it. It
seems that each somite gives SMC pro-
genitors within a locally restricted spatial
domain (Christ et al, 2004; Hungerford
et al, 1996) (Fig. 1.5).
Aortic mesoangioblast
An unexpected finding is that cells
derived from the embryonic aorta are
able to differentiate “in vitro” into ECs
and in most mesodermal tissues. In
2002, Minasi et al. identified a new
type of resident stem cell inside the dor-
sal aorta wall in quail embryos capa-
ble of self renewal and to incorporate
into mesodermal tissues after grafting of
quail or mouse embryonic aorta into host
chick embryos. For this reason and for
the expression of myogenic and endothe-
lial markers they called this cell mesoan-
gioblast. Based on these data, they
proposed that during tissue histogene-
sis, when vessels penetrate into develop-
ing tissues, vessel-associated progenitors,
which possibly originate from a common
ancestor (mesoangioblast, rather than
hemoangioblast) would leave the growing
vessels and adopt the fate of the tissue
where the vessel has entered responding
to environmental stimuli (Minasi et al,
2002). Actually, the existence of mesoan-
gioblasts in adult tissues has not yet been
reported, but many research groups are
looking at a similar class of blood vessel
associated stem cells in humans (Cossu




2.1 Definition and classification of
Stem Cells
Stem cells (SCs) differ from other cells
type in the body since it is an undiffer-
entiated cell that has the ability to di-
vide (self replicate) for indefinite peri-
ods—often throughout the life of the or-
ganism. Under the right conditions, or
given the right signals, stem cells can give
rise (differentiate) to the many different
cell types that make up the organism.
That is, stem cells have the potential to
develop into mature cells that have char-
acteristic shapes and specialized func-
tions, such as heart cells, skin cells, or
nerve cells. Many of the terms used to de-
fine stem cells depend on the behavior of
the cells in the intact organism (in vivo),
under specific laboratory conditions (in
vitro), or after transplantation in vivo, of-
ten to a tissue that is different from the
one from which the stem cells were de-
rived. For example, the fertilized egg is
said to be totipotent because it has the
potential to generate all the cells and tis-
sues that make up an embryo and that
support its development in utero. Most
scientists use the term pluripotent to de-
scribe stem cells that can give rise to cells
derived from all three embryonic germ
layers, mesoderm, endoderm, and ecto-
derm. Unipotent stem cell, a term that
is usually applied to a cell in adult organ-
isms, means that the cells in question are
capable of differentiating along only one
lineage. Also, it may be that the adult
stem cells in many differentiated, undam-
aged tissues are typically unipotent and
give rise to just one cell type under nor-
mal conditions (Fig. 2.1). This process
would allow for a steady state of self-
renewal for the tissue. However, if the
tissue becomes damaged and the replace-
ment of multiple cell types is required,
pluripotent stem cells may become acti-
vated to repair the damage (Chandross
et al, 2001).
2.2 Embryonic Stem Cells
Embryonic stem cells (ESCs) are derived
from the Inner Cell Mass (ICM) of blas-
tocyst stage of embryos. A normal day-
5 blastocysts consisting of 200-250 cells
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Figure 2.1. Classification and plasticity of SCs.
are used to derive ESC cultures. At this
stage, the ICM is composed of only 30
to 34 cells (Bongso A, 1996) and are ca-
pable to long-term self-renewal, while re-
taining a normal karyotype (Reubinoff et
al, 2000; Shamblott et al, 2001) and have
the potential to generate any cell type
of the body derived from all three em-
bryonic germ layers (Itskovitz-Eldor, et
al, 2000; Schuldiner et al, 2000). The
derivation of mESCs was first reported in
1981 (Evans et al, 1981; Martin, 1981),
but the derivation of human ES cell lines
was first reported in 1998 by Thomson
and colleagues which produced 5 differ-
ent ES cell lines from 14 blastocyst em-
bryos obtained by in vitro fertilization
(IVF) (Thomson et al, 1998). In the
1990s, ES cell lines from two non-human
primates, the rhesus monkey (Thomson
et al, 1995) and the common marmoset
(Thomson et al, 1996), were derived, and
these offered closer models for the deriva-
tion of human ES cells. Experience with
non-human primate ES cell lines and im-
provements in culture medium for human
IVF -produced embryos led rapidly to
the derivation of human ES cell lines in
1998 (Thomson et al, 1998). Human ES
cells can proliferate for two years through
300 population doublings (Odorico et al,
2001) or even 450 population doublings.
ESCs were defined by the presence
of several transcription factors and cell
surface protein further by cellular mor-
phology. The transcription factors Oct-4
(Octamer-4), Nanog and Sox2 (Sex de-
termining region Y-box2) (Niwa et al,
2000; Chambers et al, 2003; Avilion et
al, 2003) form the core regulatory net-
work that ensures the suppression of gene
that lead to differentiation and the main-
tenance of pluripotency (Boyer et al.,
2005). The cell surface antigens com-
monly used to identify mESCs are Stage-
Specific Embryonic Antigen-1 (SSEA-1),
the glycolipids SSEA3, SSEA4 (Hender-
son et al., 2002) and the keratan sulfate
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Figure 2.2. Derivation of a human embryonic SC line and differentiation
strategies (from Hyslop et al, 2005).
antigens Tra-1-60 and Tra-1-81 (Hender-
son et al, 2002; Carpenter et al, 2003).
Furthermore, ESCs retain their undiffer-
entiated status until they are able to form
embryoid bodies; from here they spon-
taneously start to differentiate. All the
characteristics mentioned above makes
the ES cell lines adapted for therapeu-
tic use and regenerative medicine. Cur-
rently, a major goal for embryonic stem
cell research is to control the differenti-
ation of human ES cell lines into spe-
cific kinds of cells to be used as the basis
for therapeutic transplantation, testing
drugs, or screening potential toxins. The
most-often discussed is their potential
use in transplant therapy to treat a wide
range of degenerative diseases. However,
treatments for any of these diseases re-
quire that human ESCs be directed to
differentiate into specific cell types prior
to transplant. Thus, at this stage, any
therapies based on the use of human ES
cells are still hypothetical and highly ex-
perimental (Jones et al, 2000; Peder-
sen, 1999). The potential disadvantages
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of the use of human ES cells for trans-
plant therapy include the propensity of
undifferentiated ES cells to induce the
formation of tumors (teratomas), which
are typically benign. Human ESCs could
be used to study early events in human
development and it may be possible to
identify the genetic, molecular, and cel-
lular events that lead to these problems
and identify methods for preventing them
(Jones et al, 2000;Rathjien et al, 1998)
(Fig. 2.2).
2.3 Adult Stem Cells
To resolve ethical concerns regarding the
use of ESCs in clinical practices, the
scientific community focused the atten-
tion on adult stem cells (ASCs). Today,
there is new evidence that stem cells are
present in far more tissues and organs
than once thought and that these cells
are capable of developing into more kinds
of cells than previously imagined. Adult
stem cells, like all stem cells, share at
least two characteristics. First, they can
make identical copies of themselves for
long periods of time; this ability to pro-
liferate is referred to as long-term self-
renewal. Second, they can give rise to
mature cell types that have character-
istic morphologies (shapes) and special-
ized functions. Typically, stem cells gen-
erate an intermediate cell type or types
before they achieve their fully differenti-
ated state. The intermediate cell is called
a precursor or progenitor cell. Progenitor
or precursor cells in fetal or adult tissues
are partly differentiated cells that divide
and give rise to differentiated cells. Such
cells are usually regarded as “committed”
to differentiating along a particular cellu-
lar development pathway (Robey, 2000).
Adult stem cells are rare. Their primary
functions are to maintain the steady state
functioning of a cell, called homeosta-
sis, and, with limitations, to replace cells
that die because of injury or disease
(Hunt et al, 1987; Leblond, 1964). Fur-
thermore, adult stem cells are dispersed
in tissues throughout the mature animal
and behave very differently, depending
on their local environment. For exam-
ple, HSCs are constantly being generated
in the bone marrow where they differ-
entiate into mature types of blood cells
(Domen et al, 1999). In contrast, stem
cells in the small intestine are station-
ary and are physically separated from the
mature cell types they generate. These
epithelial crypt cells divide fairly often,
but remain part of the stationary group
of cells they generate (Slack, 2000). Un-
like embryonic stem cells, which are de-
fined by their origin, no one knows the
origin of adult stem cells in any mature
tissue. Some have proposed that stem
cells are somehow set aside during fetal
development and restrained from differ-
entiating. As documented below, the list
of adult tissues reported to contain stem
cells is growing and includes bone mar-
row, peripheral blood, brain, spinal cord,
dental pulp, blood vessels, skeletal mus-
cle, epithelia of the skin and digestive
system, cornea, retina, liver, and pan-
creas. In order to be classified as an adult
stem cell, the cell should be capable of
self-renewal for the lifetime of the organ-
ism. This criterion, although fundamen-
tal to the nature of a stem cell, is diffi-
cult to prove in vivo. Ideally, adult stem
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cells should also be clonogenic and able
to give rise to fully differentiated cells
that have mature phenotypes, are fully
integrated into the tissue and are capa-
ble of specialized functions that are ap-
propriate for the tissue. The term plas-
ticity means that a stem cell from one
adult tissue can generate the differen-
tiated cell types of another tissue. At
this time, there is no formally accepted
name for this phenomenon in the scien-
tific literature. It is variously referred
to as “plasticity” (Brazelton et al, 2000;
Krause et al, 2001), “unorthodox differ-
entiation” (Bianco et al, 1999) or “trans-
differentiation” (Anderson et al, 2001;
Lagasse et al 2000). The differentiated
cell types that result from plasticity are
usually reported to have the morpholog-
ical characteristics of the differentiated
cells and to display their characteristic
surface markers. Many plasticity exper-
iments involve injury to a particular tis-
sue, which is intended to model a particu-
lar human disease or injury (Bjornson et
al, 1999; Lagasse et al, 2000; Orlic et al,
2001). However, there is limited evidence
to date that such adult stem cells can
generate mature, fully functional cells or
that the cells have restored lost function
in vivo (Lagasse et al 2000). Most of
the studies that show the plasticity of
adult stem cells involve cells that are de-
rived from the bone marrow (Brazelton
et al, 2000; Lagasse et al 2000; Ferrari et
al, 1998; Peterson et al, 1999) or brain
(Bjornson et al, 1999; Clarke et al, 2000)
(Fig. 2.3).
Figure 2.3. Multipotency and use of ASCs (from http://stemcells.nih.gov).
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2.4 Mesenchymal Stem Cells
The adult bone marrow contains not only
the hematopoietic stem cells, but also
Mesenchymal Stem Cells (MSCs) that
represent an archetype of multipotent
adult stem cell capable of giving arise to
a number differentiated mesodermal cells
of various type, including chondrocytes,
osteocytes, adipocytes, myocytes and
bone marrow stromal cells (Deans et al,
2000; Pittenger et al, 1999); that can be
promising for their application in regen-
erative medicine. Interest in MSCs be-
gan over 130 years ago when Cohnheim,
a German pathologist, suggested that the
bone marrow gave rise to fibroblast-like
cells during the repair process (Ross et
al, 1970; Petrakis et al, 1961). Later
in 1976, Friedenstein described first the
fibroblast precursor from bone marrows
capable of osteogenesis. Since their orig-
inal description, these bone marrow mul-
tipotent progenitors were known with dif-
ferent names (Castro-Malaspina et al,
1980; Piersma et al, 1985; Kuznetsov
et al, 1997; Prockop et al, 1997; Ca-
plan et al, 1994; Conget et al, 1999).
An attempt to clarify the nomenclature
for MSCs has recently been proposed
by the International Society for Cellular
Therapy and discussed at several interna-
tional meetings such as Adult Mesenchy-
mal Stem Cells in Regenerative medicine
(MSC 2007, http://www.msc2007.net).
In bone marrow, MSCs are important
components of the HSCs niche. In fact,
all niches components like stroma, stro-
mal cells (endothelial cells, adipocytes,
macrophages, reticular cells, fibroblasts
and osteoprogenitors) and cellular mi-
croenvironment, where MSCs are pre-
sumed to exist in a small percentage (es-
timated at about 0.001-0.01%), ensure
the survival and growth of HSCs (Koller
et al, 1997; Strobel et al, 1986; Tavas-
soli et al, 1982). Although MSCs were
originally isolated from bone marrows
(Friedenstein et al, 1966; Pittenger et al,
1999), similar populations reside in a dif-
ferent numbers of adult and fetal (In ’t
Anker et al, 2003) tissues, including the
spleen, amniotic fluid, cartilage, muscle,
Figure 2.4. Morphological properties of in vitro MSCs (image taken from
VW-MSCs culture).
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tendons, peripheral blood (Zvaifler et al,
2000; Kuznetsov et al, 2001) and tis-
sue adipose (Zuk et al, 2001; Alhadlaq
et al, 2004) and more recently from de-
ciduous tooth, fetal membrane (Zhang et
al, 2004) and umbilical cord (Bieback et
al, 2004; Kogler et al, 2004). In general,
MSCs have been defined by their plastic
adherent growth and subsequent expan-
sion under specific culture conditions, by
a panel of non-specific surface antigens
reported below and by their in vitro e in
vivo differentiation potential (Javazon et
al, 2004) (Fig. 2.4).
Although there are not specific mark-
ers MSCs, many attempts have been
made to develop a cell-surface antigen
profile to improve the purification and
identification of MSCs. Minimal criteria,
to define human MSCs proposed by the
Mesenchymal and Tissue Stem Cell Com-
mittee of the International Society for
Cellular Therapy (Dominici et al., 2006),
are the positivity for the following anti-
gens:
• CD105: the antibody SH2 iden-
tifies an epitope of endoglin
(CD105), the Transforming growth
factor beta (TGFβ) receptor III
presents on endothelial cells, ery-
throblasts, monocytes, and connec-
tive tissue stromal cells which fa-
cilitates enrichment of stromal pro-
genitors from bone marrow (Short
et al, 2003);
• CD73: a glycoprotein, identified
by monoclonal antibody SH3 and
SH4, involved in B-cell activation
(Short et al, 2003). It is ex-
pressed by lymphocytes and en-
dothelial cells;
• CD90 or Thy1: a 25–37 kDa
heavily N-glycosylated, glycophos-
phatidylinositol (GPI) anchored
conserved cell surface protein, orig-
inally discovered as a thymocyte
antigen. Thy-1 can be used as a
marker for a variety of stem cells
and for the axonal processes of ma-
ture neurons. Structural study of
Thy-1 lead to the foundation of the
immunoglobulin superfamily.
In contrast, the MSCs are negative
for other markers of the hematopoietic
lineage including CD34 (a transmem-
brane protein that defined ˜ 1% of nor-
mal bone marrow mononuclear cells in-
cluding hematopoietic precursors/stem
cells and normal endothelial cells and
its is considered a primitive HSCs
marker); CD31(a glycoprotein also de-
signed platelet endothelial cell adhesion
molecule-1 (PECAM-1) that is normally
expressed on endothelial cells, circulating
and tissutal hematopoietic cells including
platelets, monocytes/macrophages, gran-
ulocytes and B-cells); CD45 (a leukocyte
common antigen exclusively expressed
on the surface of almost all haemato-
lymphoid cells and their progenitors)
and CD14 or CD11b (an immune cell
marker).
The identification of a definitive
marker that allows the isolation of
MSCs from fresh tissue could be very
important. Stro-1 is the best-know
MSC marker because the cell popula-
tion negative for Stro-1 is not capa-
ble to form colonies. Stro-1 positive
cells can become HSC-supporting fibrob-
lasts, smooth muscle cells, adipocytes,
26
2 – Stem Cells
Figure 2.5. The mesengenic process of MSCs (modified from Caplan, 2009).
osteoblasts and chondrocytes (Dennis et
al, 2002) which reinforce the functional
role of MSCs. However, Stro-1 is not
specific for these cells and its expression
in MSCs is gradually lost during cul-
ture expansion (Gronthos et al, 2003),
so the Stro-1 labeling to isolate and/or
identificate MSCs it is possible only dur-
ing early passages. In some cases, other
cell surface markers have been empiri-
cally used to isolate the human bone mar-
row mononuclear cells by fluorescence-
activated cell sorting (FACS) or mag-
netic bead cell sorting based both on the
expression of several markers including
CD49b, CD146, CD130, CD200, CD44
and CD166.
Since that were first discovered, sev-
eral studies demonstrated the multilin-
eage differentiation potential of MSCs
populations showing their capacity to de-
velop into terminally differentiated mes-
enchymal phenotypes including bone (
Bruder et al, 1997), cartilage (Kadiyala
et al, 1997), tendon (Young et al,
1998), muscle (Ferrari et al, 1998),
adipose tissue (Dennis et al, 1999)
and hematopoietic-supporting stroma
(Prockop et al, 1997) and showing also
a high degree of plasticity (D’Ippolito et
al, 2004, Zhao et al, 2002) (Fig. 2.5).
The lineage-committed cell progresses
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through several stages of maturation pro-
cess to a terminal differentiation, which
is characterized by the cessation of pro-
liferative capacity and the synthesis of
tissue-specific markers, including compo-
nents of the extracellular matrix (ECM)
(Baksh et al, 2004).
In the 1999, Pittenger et al reported
that only one-third of the initial ad-
herent BM-MSCs clones are pluripotent
(osteo/chondro/adipo) (Pittenger et al,
1999). Furthermore, non-immortalized
cell clones have been used to investi-
gate the nature and properties of com-
mitted progenitors present in culture of
BM-MSCs. This study demonstrated
that 30% of all clones exhibited a tri-
lineage (osteo/chondro/adipo) differen-
tiation potential, while the remainder
displayed a bi-lineage (osteo/chondro)
or uni-lineage (osteo) (Muraglia et al,
2000). The heterogeneity, both in vivo
and in vitro studies, could be explained
by the notion that MSCs in the bone
marrow (and likely in all tissues) are a
pool of cells that include MSCs and dif-
ferent subpopulations at different state
of differentiation. During differentiation,
the proliferative potential of these differ-
ent MSCs decreases and, depending on
the initial state of differentiation, both
proliferative and multilineage potential
become limited (Baksh et al, 2004).
As regarding the immunological pro-
file, MSCs express intermediate levels of
human leukocyte antigen (HLA) class I
molecules major histocompatibility com-
plex (MHC) and low levels of class II
HLA and Fas ligand; they do not express
the costimulatory molecules B7-1, B7-2,
CD40, or CD40L. The immunosuppres-
sive nature of MSCs is of clinical rele-
vance in allogeneic transplantation since
it could reduce the incidence and severity
of graft-vs-host disease (GVD) (Le Blanc
et al, 2003 a, b). Clinically, the easy
of isolation, expansion potential, migra-
tory capacity and immunosuppressive ca-
pability of MSCs has made them a pop-
ular cell type for investigating regener-
ative medicine, gene therapy and tissue
engineering. Several studies based on
animal transplantation, shown that ex-
vivo expanded MSCs were able to dif-
ferentiate into cells of the residing tis-
sue, to repair damaged tissue and to re-
store partially its normal function, gen-
erating promising results for the treat-
ments of several illness, including bone
(Mauney et al, 2005), cardiovascular and
brain disease (Zimmet et al, 2005). Re-
cent studies demonstrated that the ther-
apeutic contribution of MSCs transplan-
tation could be caused not only by direct
differentiation but also by paracrine ac-
tivities which supply with large amounts
of cytokines and growth factors. These
bioactive factors suppress the local im-
mune system, inhibit apoptosis and en-
hance angiogenesis (Caplan et al, 2006).
MSCs are promising also for tissue en-
gineering. Bioengineered structures with
a defined shape made with biomaterials
like collagen type I, fibronectin, alginate,
polylactic acid and alginate can be com-
binated with MSCs, culturing in bioreac-
tors, it could be possible to obtain tis-
sue and organs (Stock et al, 2001) as re-
ported in pre-clinic animal model studies
for the treatment of a large bone defects
(Kon et al, 2000).
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2.5 Stem Cell Niches
It is well know that self renewal and
pluripotency are specific skills of adult
stem cells, but the idea that extremely
specialized external stimuli and microen-
vironment can affect the regulation of
the specific stem characteristic brought
several team to go in for it. The
niche concept was introduced in 1978 by
Schofield studies (Schofield, 1978); his
team proved that microenvironment cells
has a role in maintaining in a quies-
cent condition the hematopoietic stem
cell, and suggested the presence of a
“stem cell niche” in which stromal cells
releases growth factors that bind extra-
cellular matrix structures; in this way
target cells recognized them by specific
receptor (Gordon, 2008). This mecha-
nism permit to localize high concentra-
tion of specific growth factors in spe-
cific microenvironment areas. Several in-
creasing studies had shown the present
of a wide range of humoral factors, cy-
tokines, chemokines and adhesive factors
supporting adult stem cells. All those re-
sults suggest that stem niche not have
only a structural role, but seems to have
the intrinsic potential to lead the destiny
of the cells in it.
2.5.1 Adult Stem Cells of the
Nervous System
More than 30 years ago, Altman and
Das showed that two regions of the post-
natal rat brain, the hippocampus and the
olfactory bulb, contain dividing cells that
become neurons (Altman et al, 1965 and
1969). Despite these reports, the prevail-
ing view at the time was that nerve cells
in the adult brain do not divide. In fact,
the notion that stem cells in the adult
brain can generate its three major cell
types—astrocytes and oligodendrocytes,
as well as neurons—was not accepted un-
til far more recently. Within the past fif-
teen years, a series of studies has shown
that stem cells occur in the adult mam-
malian brain and that these cells can gen-
erate its three major cell lineages (Gage
et al, 1995; Johe et al, 1996; Temple et
al, 1999). There is now widespread con-
sensus that the adult mammalian brain
does contain stem cells. Because there
are no markers currently available to
identify the cells in vivo, the only method
for testing whether a given population
of Central Nervous System (CNS) cells
contains stem cells is to isolate the cells
and manipulate them in vitro, a process
that may change their intrinsic proper-
ties (Morrison et al, 1999). Despite these
barriers, three groups of CNS stem cells
have been reported to date. All occur
in the adult rodent brain and prelimi-
nary evidence indicates they also occur
in the adult human brain. One group oc-
cupies the brain tissue next to the ven-
tricles, regions known as the ventricular
zone and the subventricular zone. The
ventricles are spaces in the brain filled
with cerebrospinal fluid. During fetal de-
velopment, the tissue adjacent to the ven-
tricles is a prominent region of actively
dividing cells. By adulthood, however,
this tissue is much smaller, although it
still appears to contain stem cells (Mor-
shead et al, 2001). A second group of
adult CNS stem cells, described in mice
29
2 – Stem Cells
but not in humans, occurs in a streak
of tissue that connects the lateral ventri-
cle and the olfactory bulb, which receives
odor signals from the nose. In rodents,
olfactory bulb neurons are constantly be-
ing replenished via this pathway (Luskin,
1993). A third possible location for stem
cells in adult mouse and human brain oc-
curs in the hippocampus, a part of the
brain thought to play a role in the forma-
tion of certain kinds of memory (Eriksson
et al, 1998; Gage et al, 1995) (Fig. 2.6).
2.5.2 Hematopoietic Niche
The notion that the bone marrow
contains stem cells is not new. One
population of bone marrow cells, the
hematopoietic stem cells (HSCs), is re-
sponsible for forming all of the types of
blood cells in the body. HSCs were recog-
nized as a stem cells more than 40 years
ago (Becker et al, 1963; Till et al, 1961).
Bone marrow stromal cells—a mixed cell
population that generates bone, carti-
lage, fat, fibrous connective tissue, and
the reticular network that supports blood
cell formation—were described shortly
after the discovery of HSCs (Friedenstein
et al, 1966; Owen et al, 1988). The mes-
enchymal stem cells of the bone marrow
also give rise to these tissues, and may
constitute the same population of cells
as the bone marrow stromal cells (Pit-
tenger et al, 2001). Recently, a popu-
lation of progenitor cells that differen-
tiates into endothelial cells, a type of
cell that lines the blood vessels, was iso-
lated from circulating blood (Asahara et
al, 1997) and identified as originating in
bone marrow (Shi et al, 1998). Whether
these endothelial progenitor cells, which
resemble the angioblasts that give rise to
blood vessels during embryonic develop-
ment, represent a bona fide population
of adult bone marrow stem cells remains
uncertain. Thus, the bone marrow ap-
pears to contain three stem cell popu-
lations—hematopoietic stem cells, stro-
mal cells and endothelial progenitor cells.
Two more apparent stem cell types have
been reported in circulating blood, but
have not been shown to originate from
the bone marrow. One population, called
pericytes, may be closely related to bone
marrow stromal cells, although their ori-
gin remains elusive (Bianco et al, 2001).
The second population of blood born
stem cells, which occur in four species
ofanimals tested—guinea pigs, mice, rab-
bits, and humans—resemble stromal cells
in that they can generate bone and fat
(Kuznetsov et al, 2001). This replenish-
ment process occurs largely in the bone
marrow, where HSCs reside, divide, and
differentiate into all the blood cell types.
Both HSCs and differentiated blood cells
cycle from the bone marrow to the blood
and back again, under the influence of
a barrage of secreted factors that regu-
late cell proliferation, differentiation, and
migration. HSCs can reconstitute the
hematopoietic system of mice that have
been subjected to lethal doses of radia-
tion to destroy their own hematopoietic
systems (Becker et al, 1963; Till et al,
1961). Over the years, many combina-
tions of surface markers have been used
to identify, isolate, and purify HSCs de-
rived from bone marrow and blood. Un-
differentiated HSCs and hematopoietic
progenitor cells express c-kit, CD34, and
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H-2K. These cells usually lack the lin-
eage marker Lin, or express it at very
low levels (Lin–/low). And for transplant
purposes, cells that are CD34+ Thy1+
Lin– are most likely to contain stem cells
and result in engraftment. Two kinds
of HSCs have been defined. Long-term
HSCs proliferate for the lifetime of an an-
imal. In young adult mice, an estimated
8 to 10% of long-term HSCs enter the cell
cycle and divide each day. Short-term
HSCs proliferate for a limited time, possi-
bly a few months. Long-term HSCs have
high levels of telomerase activity (Weiss-
man, 2000). In adult humans, HSCs oc-
cur in the bone marrow, blood, liver, and
spleen, but are extremely rare in any of
these tissues. Bone marrow stromal cells
have long been recognized for playing an
important role in the differentiation of
mature blood cells from HSCs. But stro-
mal cells also have other important func-
tions (Friedenstein, 1966). In addition
to providing the physical environment
in which HSCs differentiate, BM stro-
mal cells generate cartilage, bone, and
fat (see above). Unlike HSCs, which do
not divide in vitro (or proliferate only
to a limited extent), BM stromal cells
can proliferate for up to 35 population
doublings in vitro (Bruder et al, 1997).
They grow rapidly under the influence of
such mitogens as platelet-derived growth
factor (PDGF), epidermal growth fac-
tor (EGF), basic fibroblast growth factor
(bFGF), and insulin-like growth factor-
1 (IGF-1) (Bianco et al, 2001). Like
HSCs, BM stromal cells arise from em-
bryonic mesoderm during development,
although no specific precursor or stem
cell for stromal cells has been isolated
and identified. One theory about their
origin is that a common kind of pro-
genitor cell—perhaps a primordial en-
dothelial cell that lines embryonic blood
vessels—gives rise to both HSCs and to
mesodermal precursors. The latter may
then differentiate into myogenic precur-
sors (the satellite cells that are thought
to function as stem cells in skeletal mus-
cle), and the BM stromal cells (Bianco et
al, 1999) (Fig. 2.6).
2.5.3 Epidermal Stem Cells
Niche
Skin epidermis, with its appendix hair
follicle structure, is a regenerating or-
gan with a well-organized architecture.
Each hair follicle is composed of a per-
manent portion, which includes seba-
ceous glands and the underlying bulge
area, and a dynamic renewing portion
which give arise two stem cells popula-
tion within the hair follicle and interfol-
licular regions. The first population, the
epidermal stem cell is located in the basal
layer of the skin clustered in epidermal
proliferation units (Potten, 1981), nor-
mally gives rise to stratified skin layers.
The second, hair follicle stem cells (HF-
SCs), resides in a region of the outer root
sheath called the “bulge”, and it is re-
sponsible for the regeneration of hair and
sebaceous glands, restore the epidermis
after wounding (Taylor et al, 2000; Rendl
et al, 2005) and that can be activated
during the hair cycle in response to in-
jury.
The bulge area act as a niche where
HFSCs (Niemann et al, 2002) are lo-
cated, maintained (Cotsarelis et al, 1990;
Sun et al. 1991) and also responsible for
31
2 – Stem Cells
the long-term replenishment of the inter-
follicular epidermis. Bulge stem cells are
generally quiescent, multipotent and, af-
ter their activation, giving rise to daugh-
ter cells; the daughter cells retained in
the bulge remain as stem cells while other
daughter cells migrate down to become
hair-matrix progenitors responsible for
hair regeneration (Cotsarelis et al, 1990;
Niemann et al, 2002; Oshima et al, 2001;
Taylor et al, 2000).
Another population of stem cells in
skin occurs in the basal layer of the epi-
dermis. These stem cells proliferate in
the basal region, and then differentiate
as they move toward the outer surface
of the skin. The keratinocytes in the
outermost layer lack nuclei and act as a
protective barrier. A dividing skin stem
cell can divide asymmetrically to produce
two kinds of daughter cells. One is an-
other self-renewing stem cell. The second
kind of daughter cell is an intermediate
precursor cell which is then committed
to replicate a few times before differenti-
ating into keratinocytes (Zhu et al, 1999)
(Fig. 2.6).
2.5.4 Intestinal Stem Cells Niche
The intestinal epithelium can be di-
vided into two regions, a region con-
taining pericryptal fibroblasts and mes-
enchyme functional differentiated cells
(villa) and a proliferative region (crypt
Lieberku¨hn) which represents the stem
cell niche. Intestinal regeneration be-
gins with intestinal stem cells (ISCs),
which give rise to four different types
of epithelial lineages: columnar ente-
rocytes, mucin-producing goblet cells,
Paneth cells, and enteroendocrine cells
(Bjerknes et al, 1999; Winton et al,
2000).
ISCs are generally proposed to be lo-
cated at the fourth or fifth position from
the crypt bottom, above the Paneth cells
(Booth et al, 2000; He et al, 2004; San-
cho et al, 2004). The crypt is a contigu-
ous pocket of epithelial cells at the base
of the villus. ISCs and Transit Amplify-
ing (TA) cells within the crypt regenerate
the entire villus every 3 to 5 days (Pot-
ten et al, 1990). Genetic marker shows
that crypts derive from an individual or
few ISCs and that each villus is the prod-
uct of cells the coming from several adja-
cent crypts (Gordon et al, 1992). There
are four to six ISCs per crypt that are
located in ring diameters of about four
cells from the crypt bottom. Progeny of
activated ISCs migrate upwards to be-
come TA cells. When they reach the top
of the crypt, TA cells stop proliferating
and assume their appropriate positions
within the villus structure. During post-
natal intestinal regeneration, mesenchy-
mal cells subjacent to epithelial cells play
a role in epithelial cell proliferation, dif-
ferentiation, and apoptosis; BMP4, ex-
pressed in the ISC-adjacent mesenchymal
cells, is one of the putative niche sig-
nals (He et al, 2004); endothelial cells
provide ISCs with survival signals such
as fibroblast growth factor (FGF) (Paris
et al, 2001); myofibroblasts surrounding
epithelial cells, supported ISCs “niche”
and influence other epithelial cells (Mills
et al, 2001). Molecular analysis showed
that signal Wnt plays a positive role
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Figure 2.6. In vivo distribution of Stem cells niches (from Li et al, 2005).
in the promotion of ISC activation/self-
renewal; in contrast, BMP signaling re-
stricts ISC activation and crypt cell fate
(Haramis et al, 2004; He et al, 2004)
(Fig. 2.6).
2.5.5 Skeletal muscle Stem Cells
Skeletal muscle is derived from em-
bryonic mesoderm. To date, at least
three populations of skeletal muscle stem
cells have been identified: satellite cells,
cells in the wall of the dorsal aorta, and
so-called “side population” cells (SP).
Satellite cells in skeletal muscle were
identified 50 years ago in frogs by electron
microscopy (Mauro, 1961), and there-
after in mammals (Schultz, 1976). Satel-
lite cells occur on the surface of the basal
lamina of a mature muscle cell, or my-
ofiber. In adult mammals, satellite cells
mediate muscle growth (Schultz, 1996).
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Although satellite cells are normally non-
dividing, they can be triggered to pro-
liferate as a result of injury, or weight-
bearing exercise.mediated by a rich group
of myogenic regulatory elements. A re-
cent report indicates that muscle stem
cells may also occur in the dorsal aorta
of mouse embryos, and constitute a cell
type that gives rise both to muscle satel-
lite cells and endothelial cells. Whether
the dorsal aorta cells meet the criteria of
a self-renewing muscle stem cell is a mat-
ter of debate (De Angelis et al, 1999).
Another report indicates that a differ-
ent kind of stem cell, called an SP cell,
can also regenerate skeletal muscle may
be present in muscle and bone marrow.
SP stands for a side population of cells
that can be separated by fluorescence-
activated cell sorting analysis (Gussoni
et al, 1999).
2.5.6 Stem Cells in the Pancreas
and Liver
The status of stem cells in the adult
pancreas and liver is unclear. During em-
bryonic development, both tissues arise
from endoderm. A recent study indi-
cates that a single precursor cell derived
from embryonic endoderm may generate
both the ventral pancreas and the liver
(Deutsch et al, 2001). In adult mam-
mals, however, both the pancreas and the
liver contain multiple kinds of differenti-
ated cells that may be repopulated or re-
generated by multiple types of stem cells.
In the pancreas, endocrine (hormone-
producing) cells occur in the islets of
Langerhans. They include the beta cells
(which produce insulin), the alpha cells
(which secrete glucagon), and cells that
release the peptide hormones somato-
statin and pancreatic polypeptide. Stem
cells in the adult pancreas are postulated
to occur in the pancreatic ducts or in
the islets themselves. Several recent re-
ports indicate that stem cells that ex-
press nestin—which is usually regarded
as a marker of neural stem cells—can
generate all of the cell types in the islets
(Zulewsky et al, 2001). The identity of
stem cells that can repopulate the liver
of adult mammals is also in question.
Recent studies in rodents indicate that
HSCs (derived from mesoderm) may be
able to home to liver after it is damaged,
and demonstrate plasticity in becoming
hepatocytes (usually derived from endo-
derm) (Lagasse et al, 2000; Theise et al,
2000). But the question remains as to
whether cells from the bone marrow nor-
mally generate hepatocytes in vivo. It
is not known whether this kind of plas-
ticity occurs without severe damage to
the liver or whether HSCs from the bone
marrow generate oval cells of the liver
(Crosby et al, 2001). Although hepatic
oval cells exist in the liver, it is not
clear whether they actually generate new
hepatocytes (Thorgeirsson, 1993). Oval
cells may arise from the portal tracts in
liver and may give rise to either hepato-
cytes(Lazaro et al, 1998) and to the ep-
ithelium of the bile ducts (Germain et al,
1988). Indeed, hepatocytes themselves,
may be responsible for the well-known re-




The development of new vessels from
progenitor cells, i.e., angiogenesis, is
not limited to embryogenesis (Carmeliet,
2003). Adult vessels are physiologi-
cally exposed to mechanical forces and
shear stresses that can damage the vas-
cular wall; as a result vascular wall Cells
(VWCs) growth and repair are neces-
sary during life. Furthermore chronic
vascular injuries are associated with ar-
terial wall diseases, e.g., atherosclero-
sis, post-graft arteriosclerosis, aneurys-
mal dilatation, in-stent restenosis,; un-
der these pathological circumstances not
only VWCs but also their progenitors are
involved in the early and late arterial
wall disease development. As a conse-
quence, the identification and character-
ization of progenitors involved in physio-
logical homeostasis and pathological vas-
cular remodelling is an issue of great in-
terest involving the modern fields of re-
pair or regenerative medicine and tissue
engineering. In 2006 was suggested the
existence of a “vasculogenic niche” in the
human vascular wall of large and mid-
sized blood vessels. The existence of this
“vasculogenic zone” has been defined as
a vascular mural zone, identified in adult
human vascular wall and located at the
border between the media and the ad-
ventitial layers containing a complete hi-
erarchy of resident stem cells, which may
serve as a source for progenitor cells for
postnatal vasculogenesis (Zengin et al,
2006) (Fig. 3.1).
3.1 Vascular wall resident En-
dothelial Progenitors
Most of the knowledge about resident
vascular progenitors comes from animal
models, even though more recent studies
are shedding light on their presence and
role in the human vascular wall.
Pivotal studies by Alessandri and
colleagues investigated the angioform-
ing capacity of human embryonal aorta
through ring assay. Under this exper-
imental condition, capillary-like struc-
tures expressing markers of endothelial
differentiation sprouted from the outer
layer of aortic rings raising the possibil-
ity that immature endothelial precursor
cells could be present in the vessel wall.
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This hypothesis was confirmed by in vitro
differentiation of CD34+/CD31- vessel
wall isolated cells into mature endothe-
lial cells (Alessandri et al, 2001). Simi-
lar results were recently obtained on fetal
tissue. In fact, vascular progenitor cells
residing in the human fetal aorta were
able to give rise to endothelial and mu-
ral cells in response to Vascular Endothe-
lial Growth Factor (VEGF) and Platelet-
Derived Growth Factor-BB (PDGF-BB)
respectively and to improve neovascular-
isation in a murine model of peripheral
ischemia(Invernici et al, 2007).
In 2005 Ingram et al. found that
human mature ECs contain a subpopu-
lation of EPCs allegedly organized in a
completely hierarchical manner with dif-
ferent clonogenic and proliferative poten-
tial (Ingram et al, 2005). This finding
is very intriguing because it refers to an
adult cell population which is supposed
to have a low turnover in normal ves-
sels; adult ECs are indeed reported to
undergo mitosis in less than 1% of the
overall cell compartment daily (Schwartz
et al, 1977).
A crucial evidence for the presence
of EPCs in the adult vascular wall is
provided by the study of Zengin et al.
who identified in the human internal tho-
racic artery (HITA) a vasculogenic area
located between the media and adventi-
tia layers; according to the authors this
area may serve as a source for progenitor
cells suited for postnatal vasculogenesis,
i.e., the growth of new vessels from pre-
existing ones. Consistent with this hy-
pothesis, ring assays demonstrated that
CD34+ cells of the HITA-wall form cap-
illary sprouts ex vivo both in the external
surface and in the internal lumen (Zengin
Figure 3.1. The vascular wall niche (from Zengin et al, 2006).
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et al, 2006).
3.2 Vascular wall resident SMC
progenitors
The integrity and synchronized activity
of the smooth muscle layer is also essen-
tial for vascular functionality as it insures
the correct haematic flow to the periph-
eral tissues. The composition of adult
media reflects the different embryologi-
cal origins of SMCs. Indeed they differ in
morphology, cytoskeletal-contractile pro-
tein expression and production of peptide
growth factors (Chamley-Campbell et al,
1979). Growth and remodelling of blood
vessels after birth is due to migration and
proliferation of resident progenitor cells
according to embryogenesis. Actually lit-
tle is known about the exact identity and
location of SMC progenitors in human
vessels even though their existence in the
vascular wall of adult animals has been
demonstrated.
Sainz et al., in 2006, demonstrated
the presence of endothelial and smooth
muscle progenitor cells in healthy arter-
ies of adult mice. Researchers selected
the progenitors as a Hoechst 33342 neg-
ative fraction in flow cytometry on to-
tal cells extracted from murine aorta
and then differentiate them with VEGF
and PDGF-BB or TGF-β1 (Sainz et al,
2006).
In another study, immunohistochem-
ical staining revealed that the adven-
titia in murine aortic roots contains a
large numbers of cells expressing stem
cell markers as Sca-1. These cells can dif-
ferentiate into SMCs in a PDGF-BB de-
pendent manner. It seems that vascular
wall contains smooth muscle progenitors
that can replace dead or malfunctional
cells (Hu et al, 2004).
According to these results, the SMC
progenitor should belong to a multipo-
tent stem cell population since both ani-
mal studies obtained a SMC lineage able
to give origin to endothelial and smooth
muscle cells. Furthermore, from em-
bryological studies emerge the possibil-
ity that endothelial and smooth mus-
cle cells may also share a common ori-
gin from a bipotent precursor cell (Ya-
mashita et al, 2000; Ferreira et al, 2007).
Flk1+ murine ESCs (Yamashita et al,
2000) and CD34+ human ESCs (Fer-
reira et al, 2007) isolated from embryonic
bodies originate endothelial and smooth
muscle-like cells in vitro (Yamashita et
al, 2000; Ferreira et al, 2007) and form
functional microvessels in vivo (Ferreira
et al, 2007). Although single cell isola-
tion procedures and parallel divergence
of their progeny were not performed in
both studies quoted above, this possibil-
ity can not be ruled out.
Another possibility is that some
smooth muscle progenitors in adult ves-
sels may be commissioned from peri-
cytes. Howson et al. isolated mesenchy-
mal cells from rat aortas, expressing im-
mature pericyte markers at basal level,
that form spheroid colonies “in vitro”
when cultured in serum free medium sup-
plemented with basic-Fibroblast Growth
Factor (b-FGF), whereas they acquire ex-
pression of SMC marker proteins and dif-
ferentiate in pericytes when exposed to
serum, PDGF-BB or when cultured with
angiogenic outgrowths of rat aorta and
ECs (Howson et al, 2005).
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Recent studies about postnatal neo-
vascularization suggest the possibility to
obtain smooth muscle progenitors also in
circulating blood (Simper et al, 2002),
bone marrow (Sata et al, 2002), skeletal
muscle (Maika et al, 2003) and fat tissue
(Rodriquez et al, 2006).
Altogether these studies indicate that
development of vascular SMCs from pro-
genitors does not occur exclusively dur-
ing embryogenesis; vascular resident pro-
genitor cells can replace immediately
damaged cells owing to normal physiol-
ogy, and vascular progenitor cells from
peripheral tissues are mobilized effi-
ciently in case of severe arterial trauma
(Yamashita et al, 2000).
3.3 Vascular wall resident mes-
enchymal stromal cells
It can not be excluded that additional
multipotent progenitors are involved in
ECs and SMCs generation; actually an
angiogenic and leiomyogenic differentia-
tion has been obtained from human vas-
cular wall resident mesenchymal stem
cells (Pasquinelli et al, 2007 a; Hoshino
et al, 2008; Covas et al, 2005); also a cell
endowed with a multipotency equivalent
to that of the mesoangioblast described
in the quail embryonal dorsal aorta could
be involved (Minasi et al, 2002; Cossu et
al, 2003). The vasculogenic area which
is present in the vascular wall between
the media and adventitia layers presents
many niche-like characteristics and there-
fore could be the place where smooth
muscle progenitors are located; this is
also in agreement with the hypothesis
that this same area could contain stem
cells, capable to differentiate into ma-
ture ECs, hematopoietic and local im-
mune cells, such as macrophages (Zengin
et al, 2006), and MSCs whose presence
in the adult vessel wall of animal and hu-
man tissues (Pittenger et al, 1999; Zuk
et al, 2001; Jones et al, 2004; Schultz et
al, 1994; Erices et al, 2000; Zhang et al,
2004; Alviano et al, 2007) is still matter
of debate.
Tintut at al. first demonstrated that
MSCs are present also in the adult an-
imal vessels; in fact, they isolated mul-
tipotent cells from the tunica media of
the bovine aorta. These cells, also known
as calcifying vascular cells (CVCs), dis-
play not only osteoblastic potential, but
also chondrogenic, leiomyogenic and stro-
mogenic potential under specific experi-
mental conditions (Tintut et al, 2003).
More recently our group described the
presence of Vascular Wall resident mes-
enchymal stem cells (VW-MSCs) in nor-
mal human adult thoracic aortas. Cryop-
reserved thoracic aortas harvested from
heart-beating multiorgan donors were
initially investigated for evaluating the
VWC resistance to cryoinjury: the vast
majority of VWCs, i.e. ECs and SMCs,
were irreversibly injured (Pasquinelli et
al, 2006); interestingly the only cells
in the cryopreserved arterial wall which
still remained viable at 4 days of or-
gan culture were capillary structures lo-
cated in between the media and adventi-
tia layers; therefore microvascular stress-
resistant cells are endowed in this arte-
rial zone; the immunohistochemical anal-
ysis of the CD34+/CD31- vasculogenic
layer previously described by Zengin in
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Figure 3.2. Characteristics and cell composition of vascular wall niche (from Kolf
et al, 2007 and Pacilli et al, 2009).
HITA confirmed the presence of an anal-
ogous well-developed plexus of CD34+
cells also in the aorta and the femoral
artery as well; single immunostainings
on serial sections supported the presence
of CD34+ cells possibly corresponding
to the resident CD34+/CD31- endothe-
lial progenitors reported in HITA. Beside
its presumptive vasculogenic post-natal
ability this area was richly endowed with
highly expressing HLA-I (Pasquinelli et
al, 2007 b) small calibre vessels and
therefore could act as a strategic area for
the recruitment of blood circulating cells;
accordingly we observed the presence of
bone marrow-derived CD45+ mononu-
clear cells; additional experiments also
revealed the presence of CD68+ and
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S-100+ perivascular cells representing
resident macrophages and dendritic ac-
cessory cells. Moreover, this area has
some characteristics, e.g., a discrete mor-
phology, a strategic location at the inter-
face between media and adventitia lay-
ers, an heterogeneous and complex cell
composition, an unexpectedly elevated
cell proliferation under normal condition,
a selective localization of cells express-
ing the stem cell surface molecule c-kit
which makes it unique in the arterial wall
and consistent with a niche-like function
(Pacilli et al, 2009) (Fig. 3.2). The
niche concept may explain why a cell
population sharing many properties with
bone marrow-derived MSCs can be iso-
lated and expanded in vitro from the aor-
tic arch, thoracic aorta and femoral artey
(Pasquinelli et al, 2007 a; Pasquinelli et
al, 2010), pulmonary artery (Hoshino et
al, 2008) and saphena vein (Covas et al,
2005). Furthermore, the multipotency of
these VW-MSCs which have been found
to have angiogenic (Pasquinelli et al,
2007 a), adipogenic, osteogenic, chon-
drogenic and myogenic (Hoshino et al,
2008; Covas et al, 2005; Pasquinelli et
al, 2010) potential could have implica-
tions in the development of ectopic tis-
sues like cartilage, marrow and fat tissue
in vascular disease and atherosclerosis.
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Therapeutic Potential Of Vascular
Progenitor Cells
4.1 Angiogenesis
Vessel formation occurs mainly through
two mechanisms: vasculogenesis and an-
giogenesis. Vasculogenesis represents de
novo formation of blood vessels during
embryonic development. As previously
described, mesoderm derived stem cells
(hemangioblast) first form aggregates
(blood islands) and then develop into
primitive hematopoietic and endothelial
cells (angioblasts). The angioblasts, un-
differentiated precursor cells, proliferated
and differentiated in situ into endothe-
lial cells to form a vascular labyrinth
(Carmeliet, 2000). In postnatal life adult
angioblasts seem to be present even if
their location and characterization must
be determine. On the other hand, the
formation of new vessels from preexist-
ing vessels is called angiogenesis, which
is more frequent in adult life although
vasculogenesis may also occur. Angio-
genesis is a tightly regulated process re-
quired for a number of physiological pro-
cesses like wounf healing, ovulation and
menstruation as well as embryonic devel-
opment. Excessive angiogenesis is seen
in a wide range of diseases including
tumors, inflammatory disease and dia-
betic retinopathy (Kiumura et al., 2003).
Angiogenesis is a very complex mecha-
nism including different steps. It starts
with vasodilatation, a process involving
nitric oxide. The increased permeabil-
ity leads to a preexisting vessel desta-
bilization and to a loss of the endothe-
lial cell interactions. Different angio-
genic growth factors are released. These
molecules activate metallo proteinases,
which are crucial for extracellular ma-
trix degradation. After this, endothe-
lial cells proliferate and migrate to as-
semble in solid cords that finally ac-
quire a lumen. Subsequently, pericytes
and SMCs migrate in order to reorga-
nize the cellular interactions and com-
plete the new formed vessels architec-
ture. Angiogenic sprouting is controlled
by a balance of activators and inhibitors.
Important activator factors are VEGF,
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FGF, members of TGF-β family, IL-8
and Angiopoietin-I. Inhibitors factors are
interferon-α, β, γ, IL-12, angiostatin and
endostatin (Carmeliet, 2000) (Fig. 4.1).
4.2 MSCs and angiogenic differen-
tiation
Nowadays, the more reliable hypothesis
is that hemangioblast derived form mes-
enchymal stem cells; this hypothesis is
supported by the fact that MSCs retain
angiogenic and hemogenic ability even at
adult life. Reyes at al., in 2002 have iso-
lated a multipotent population of adult
stem cells, called MAPC (multipotent
adult progenitors cells) from the adult
bone marrow, which are able to differ-
entiate into endothelial cells and other
mesodermal tissues (Reyes at al., 2002).
Recent studies demonstrated that also
adult mesenchymal stem cells are en-
dowed with angiogenic ability. Oswald
et al. showed that human BM-MSC
are able to differentiate into cells with
phenotypic (vWF, KDR and Flt expres-
sion) and functional features of endothe-
lial cells when cultivated under conflu-
ence, presence of 2% FCS and VEGF
50ng/ml for 7 days (Oswald et al., 2004).
The angiogenic ability is not only re-
stricted to bone marrow derived cells,
but also to MSC isolated from different
sources such as vassel wall (Pasquinelli
et al, 2007 a), term amniotic membrane
(Alviano et al, 2007), dental pulp (Mar-
chionni et al, 2009), intestine (Lanzoni
et al, 2009), adipose tissue (Lin et al,
2010). Not surprisingly, fetal and adult
vascular progenitor cells are the best can-
didate for neoangiogenesis (Alessandri et
al 2001; Invernici et al, 2007; Pasquinelli
et al, 2007 a, Campagnolo et al, 2010).
We recently reported that adult thoracic
aorta derived MSCs exhibit the ability to
differentiate into endothelium in vitro. In
accordance with Oswald et al. (Oswald
et al., 2004) we used a three dimensional
Matrigel semisolid matrix to assay angio-
genesis. After 20 hrs of culture the MSCs
were able to form capillary-like structures
but this ability was strictly depended on
VEGF induction; controls always proved
negative. VEGF induction was accom-
panied by increased cell expression of
KDR, as documented by flow cytometry
and RT-PCR assays. At immunofluores-
cence, vWF intensely stained the cyto-
plasm of cells with a rounded morphol-
ogy (12 ± 3 %). Likewise, electron mi-
croscopy of the 20 hr samples showed
features consistent with a basic endothe-
lial cell employment, i.e., collections of
micropinocytotic vesicles and caveolae,
tight junctions, and immature Weibel-
Palade bodies (Pasquinelli et al, 2007 a).
4.3 Therapeutic angiogenesis for
Peripheral Arterial Disease
Peripheral arterial disease (PAD) is a
common cause of disability and mortal-
ity. Up to one third of patients are not
susceptible to traditional revasculariza-
tion and may benefit from stem cell ther-
apies. Furthermore, replacement of dead
cells exclusively by proliferation of termi-
nally differentiated neighboring endothe-
lial cells in case of massive loss of en-
dothelium is not sufficient to recover the
structural and functional integrity of the
endothelial lining. In such conditions the
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support and crucial contribution of stem
cells and endothelial or smooth muscle
progenitors is necessary. Progenitors can
reside in the vascular wall itself or can
be mobilized from the bone marrow and
delivered in the blood; in any case, pro-
genitors concentrate in the area of tissue
damage responding to local microenvi-
ronmental signals; tissue repair is then
achieved by several still debated mecha-
nisms, which include extracellular matrix
remodeling, angiogenesis and differentia-
tion of progenitors into mature and func-
tional cells.
Accumulating evidence shows the
ability of mobilized EPCs to repair in-
jured vessels of animal models (Sata et
al, 2002; Shimizu et al, 2001; Hillebrands
et al, 2001; Werner et al, 2002; Xu et
al, 2003; Griese et al, 2003; Werner et
al, 2003); however, one potential limita-
tion to the use of autologous stem cells
in clinical application is their low num-
ber and the documented decline in the
number and function with aging (Riha
et al, 2005; Sethe et al, 2006) and dis-
ease (Hristov et al, 2003; Fadini et al,
2006). These shortcomings can be over-
come by increasing the number of cir-
culating EPCs through pharmacological
administration of growth factors, such
as granulocyte colony-stimulating factor
(G-CSF) or VEGF, which activate pro-
genitor cell releasing factors that are able
to promote the mobilization of stem cells
from the bone marrow. Alternatively,
Mononuclear cells from peripheral blood
(PB-MNCs) can be harvested for in vitro
expansion and differentiation and then
Figure 4.1. Angiogenesis and arteriogenesis (from Carmeliet, 2000).
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transfused back into the patient. Thus,
stem cell therapy is a realistic option for
the treatment of vascular diseases.
Transfusion of ex vivo expanded
EPCs (Wassmann et al, 2006) or endoge-
nous mobilization of them (Werner et al,
2002; Kong et al, 2004; Vasa et al, 2001)
enhances reendothelialization in different
models of endothelial denudation. More-
over, EPCs may also contribute to angio-
genesis in wound healing, tissue ischemia,
or myocardial infarction. Delivery of
bone marrow derived Lin-/c-kit+ cells
onto the border of an infarct promotes
angiogenesis in situ (Orlic et al, 2001),
and intramuscular (IM) injection of bone
marrow-mononuclear cells (BM-MNCs)
into the ischemic limbs of rat and mouse
induces collateral vessel formation (Iba et
al, 2002; Kalka et al, 2000). Some in
vivo functional approaches have already
been applied in clinical trials, mainly in-
volving patients with myocardial infarc-
tion; these trials are extensively reviewed
elsewhere (Boyle et al, 2006; Oettgen et
al, 2006). In a recent review, Pacilli et
al have focused on the less covered field
of promoting angiogenesis in peripheral
vascular disease through the use of stem
cell, protein, and gene therapies; inno-
vative attempts at using stem cell engi-
neered biomaterials are also dealt with
(Pacilli et al, 2010).
A more recent metanalysis of the
literature examined all 37 clinical tri-
als on autologous cell therapy in pa-
tients with PAD; they found that autol-
ogous cell therapy was effective in im-
proving surrogate indexes of ischemia,
subjective symptoms and hard endpoints
(ulcer healing and amputation). On
the contrary, G-CSF monotherapy was
not associated with significant improve-
ment in the same endpoints. Patients
with thromboangitiis obliterans showed
some larger benefits than patients with
atherosclerotic PAD. Furthermore, the
intramuscular route of administration
and the use of bone marrow cells seemed
somehow more effective than intrarterial
administration and the use of mobilized
peripheral blood cells. Anyway, all these
procedures were well tolerated and gen-
erally safe (Fadini et al, 2010).
On the whole, the results obtained so
far may help in finding a way to success-
fully manage threatened ischemic limbs.
Most studies seem inadequately catego-
rized in their clinical presentation and,
therefore, are of little practical signifi-
cance for the expert vascular surgeon.
Larger, placebo-controlled, randomized
multicenter trials need to be planned and
conducted to confirm these findings. In
order to obtain clinically useful informa-
tion and to promote meaningful research
in this promising field, more strict in-
teraction between “pure” researchers and
specialized vascular surgeons should be
encouraged. Candidates for therapeutic
angiogenesis should be chosen from the
really threatened ischemic limb category
in order to avoid possible misinterpreta-
tion with a benign course of a mild ar-
teriopathy. Such patients should be un-
favorable candidates for other kinds of
known vascular procedures in order to
avoid ethical conflicts in treating them.
In this sense, therapeutic angiogenesis
treatment may be tested on patients un-
dergoing surgical or endovascular revas-
cularization and compared with patients
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treated similarly without the adjunct of
this novel therapy, thus comparing possi-
ble differences in the healing of ischemic
lesions. To this end, vascular centers
with high turnover and expertise in treat-
ing peripheral vascular disease should be
involved in designing and carrying out
the clinical arm of research into these in-
novative strategies (Pacilli et al, 2010).
In the future we cannot exclude that
the injection of native vascular progeni-
tor cells could provide a new way to treat
ischemic diseases. Some groups have suc-
cessfully tested in vivo the myogenic and
vasculogenic properties of Vascular Pro-
genitor Cells (VPCs) by using a murine
model of peripheral ischemia and ob-
served that VPCs transplantation into is-
chemic muscles significantly ameliorates
the clinical outcome of ischemic mice (In-




Role of Vascular Progenitor Cells
in Vascular Calcification
5.1 Biology of vascular calcifica-
tion
The arterial wall is one of the most fre-
quent location of pathological insults in
humans; the balance between injury and
repair is altered by acute and chronic
stresses, the atherosclerosis being the
major disease of the arterial wall; vas-
culitis, aneurysmal dilatation, dysplasia
and even neoplasms are additional ex-
amples of diseases that can affect irre-
versibly the arterial wall. As in bone, en-
dothelial, mesenchymal, and hematopoi-
etic cell lineages control vascular min-
eral accumulation, with cellular activities
entrained to morphogenetic, metabolic,
inflammatory and mechanical demands
placed on each vascular segment (Abedin
et al, 2004). Vascular calcification was
previously considered to be a purely de-
generative, passive process, without bi-
ological regulation. However, the cur-
rent view is that vascular calcification
is a biologically regulated process that,
like osteogenesis, involves both activators
and inhibitors. The concept that vascu-
lar calcification is related to osteogene-
sis is not unexpected, given the interac-
tion of vascular and bone cells in nor-
mal embryonic skeletogenesis. In em-
bryonal development, endochondral os-
sification follows invasion of neoangio-
genic vessels into calcified cartilage ma-
trix. Once the vasculature is established,
preosteoblasts, originating from the an-
giogenic pericytes surrounding the vascu-
lature or from blood-borne mesenchymal
cells, differentiate and initiate mineral-
ization (Gerber et al, 2000) (Fig. 5.1).
Vessel wall osteoprogenitor cells
known as calcifying vascular cells (CVCs)
can form bone matrix proteins and cal-
cified nodules, analogous to osteoblastic
differentiation in bone. These cells have
been isolated from the tunica media of
bovine and human arteries, and both
in-vitro tissue culture models and mouse
models of vascular calcification have been
established(Jacoby et al, 2000). Ectopic
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Figure 5.1. Outline of the major genetic, molecular, cellular, and endocrine me-
diators of bone remodeling (from Doherty et al, 2004).
bone in the artery wall is dramatic ev-
idence of mesenchymal cell plasticity.
Eghbali-Fatourechi and colleagues re-
cently identified circulating osteoblas-
tic cells using antibodies to osteocalcin
(OCN) or alkaline phosphatase (AP).
OCNpos cells consist of two distinct
populations: one population exhibits
low forward/side scatter, consistent with
a small cell phenotype with low gran-
ularity, and a second population has
higher forward/side scatter (larger and
more granular cell). The smaller, low
granularity population also co-expresses
CD34, whereas the larger, more gran-
ular cells are CD34 negative. While
the concentration of OCNpos cells in-
creased with age, levels of CD34pos cells
tended to decrease, leading to a sig-
nificant increase in the ratio of OCN-
pos:CD34pos cells in peripheral blood.
Since CD34pos cells include endothelial
precursor cells that may be important
in the response to vascular injury, this
increase in the OCNpos:CD34pos ratio
in circulating cells raises the possibility
that with aging, the response to vascular
injury may potentially result in vascular
calcification, rather than repair (Eghbali-
Fatourechi et al, 2007). Given the po-
tential overlap between osteoblastic and
endothelial cells it is also possible that
precursor cells in the vasculature give
rise to osteoblastic progenitors.
Several models postulating mecha-
nisms for the formation and/or inhibi-
tion of calcification have now been pro-
posed (Doherty et al, 2003). These
are: 1) the active model; 2) the passive
physicochemical model; and 3) the ar-
terial Osteoclast-like cells (OLC) model.
The active model of arterial calcifica-
tion evolved partly from the observa-
tions, stimulated in large part by stud-
ies of Bostrom et al. (Bostrom et al,
1993), who reported the existence of
pluripotent arterial cells that they named
CVCs. The BMP signaling pathway is
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critical to proper bone formation. Mar-
shall Urist (Urist, 1965) was the first to
discover that BMPs can cause transdif-
ferentiation of mesenchymal cells into os-
teoblasts, which in turn can mediate ec-
topic bone formation. This finding has
been replicated by numerous other inves-
tigators in different models (Wozney et
al, 1988; Attisano et al, 2002). Cbfa1
is one of the transcription factors that
regulates osteoblastic differentiation and
bone formation (Komori et al, 1997;
Ducy et al, 1997). Among the many
gene targets of BMP signaling identified
to date, beside cbfa1, other transcrip-
tion factors, Distal-less5 (Dlx5) and os-
terix (Osx), are now considered to be the
master genes essential for differentiation
of mesenchymal progenitors into termi-
nally differentiated osteoblasts. As re-
garding the third model, morphological
evidence for OLCs is supported by nu-
merous evidences (Doherty et al, 2004).
Collectively, these studies suggest that
there are OLCs in arteries, but the origin
of these cells is unknown. It is possible
that OLCs could differentiate from “res-
ident” pluripotent arterial cells, but it
is equally likely that they originate from
hematopoietic precursors, such as stem
cells or cells that have differentiated from
mononuclear phagocytic lineage precur-
sors (Doherty et al, 2004). As regard the
passive mechanism, it is thought that the
onset of vascular calcification could be
determine by a number of proteins which
inhibit precipitation or chelate/sequester
ions to lessen their bioavailability. It
seems likely that in arterial calcification,
proposed models are not mutually exclu-
sive.
5.2 The Mo¨nckeberg sclerosis
Vascular calcifications have been divided
into four forms that involve 1) the
atherosclerotic intima, 2) the media of
medium and large sized arteries, 3) car-
diac valves, and 4) a widespread form
known as calciphylaxis (Vattikuti et al,
2004). The second form, known as me-
dial artery calcification (MAC) may be
found in conjunction with atherosclerotic
lesions or it may occur independently
(Shao et al, 2006). It occurs in patients
with normal serum calcium and phospho-
rus levels and this distinguishes it from
vascular calciphylaxis which is related to
high serum calcium and phosphate lev-
els that result in passive mineral depo-
sition onto elastic fibers (Vattikuti et al,
2004). Of these forms, MAC has been
most strongly associated with cardiovas-
cular events (Guzman, 2007).
There are important similarities and
differences between the two major types
of calcification in arteries (following
atherosclerosis and MAC) (Doherty et
al, 2004). Atherosclerosis is charac-
terized by chronic arterial inflamma-
tion instigated and exacerbated by dis-
ordered lipid metabolism and other well-
characterized risk factors (Libby, 2002).
Large postmortem studies have revealed
that atherosclerosis begins surprisingly
early and is ubiquitous in middle-aged
and older adults (Strong, 1986). Con-
siderable confusion has arisen in the lit-
erature from failure to properly distin-
guish two distinct types of arterial calcifi-
cation: medial arterial calcification, and
calcification associated with atheroscle-
rotic plaque. There are several basic lines
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of evidence consistent with the conclu-
sion that medial calcification is not the
same entity as plaque calcification, in-
cluding histomorphological, clinical, epi-
demiological, genetic and animal stud-
ies(Doherty et al, 2004). There may be
some common elements mediating medial
and atherosclerotic calcification; the two
are not necessarily mutually exclusive.
Mineral deposition in arteries can occur
either as a component of atheroma or in
the absence of atherosclerotic plaque. In
atherosclerotic plaque, calcification typ-
ically forms in the intima, most often
near the base of the plaque adjacent to
the medial layer of the artery. Calci-
fications near the luminal surface may
result in erosions and have been impli-
cated in plaque disruption and throm-
bosis. In contrast, calcification of the
medial layer of arteries occurs indepen-
dently of atherosclerosis (Proudfoot et al,
2001). This type of calcification, ini-
tially referred to as Mo¨nckeberg’s scle-
rosis (Mo¨nckeberg, 1903), has been fre-
quently observed radiographically with
an appearance that has been likened to
railroad tracks (Lachman et al, 1977).
Medial calcification can occur in oth-
erwise normal young patients with no
Figure 5.2. Evolving model of diabetic MAC (from Shao et al, 2006).
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overt metabolic disease (Mori et al, 1992;
Top et al, 2002), increases linearly with
age (Elliott et al, 1994), and is com-
mon in elderly patients (Lachman et al,
1977; Tohno et al, 1996). Medial cal-
cification is observed with particularly
high frequency and severity in disorders
characterized by generalized metabolic,
electrolyte, or pH derangements (Mallick
et al, 1968). The Mo¨nckeberg’s sclero-
sis typically affects arteries that are less
prone to develop atherosclerosis, such as
the abdominal visceral arteries, arteries
to the thyroid and breast, and the ar-
teries supplying the extremities, but it is
also frequently encountered in the aorta.
Vascular calcification in its early
stages develops by a process of matrix
vesicle formation then partially replaced
with osteoid synthesized by osteoblast-
like cells of mesenchymal origin, such as
the vascular smooth muscle cells (VSMC)
or pericytes. The subsequent bone min-
eralization is dependent on neovascular-
ization – angiogenesis from the adventi-
tial vasa vasorum, which acts as a cus-
tom delivery system to supply the media
with oxygen and nutrients but also sys-
temic hormones, cytokines and inflam-
matory cells to the remodeling media
and the atherosclerotic intimal disease
of atherosclerosis including ossification.
The location of CVCs in these arteries is
both in the medial and intimal layers. It
is important to note that in health the
vasa vasorum normally penetrates the
media but not the intima. In disease the
vasa vasorum invade excessively not only
the media but also the intima and this
may help to explain the detrimental pro-
cess of intimal ossification.
Emerging evidence indicates that vas-
cular osteogenic signals, initiated by ad-
ventitial BMP2/Msx2 actions, are con-
centrically conveyed to the calcifying tu-
nica media via the vasa vasorum (Shao
et al, 2005; Hu et al, 2004). Dys-
metabolic signals upregulate BMP2/4
production by pericytes and endothelial
cells in the vessel wall; this promotes
adventitial Msx2/Wnt signaling. Subse-
quently, enhanced adventitial Wnt pro-
duction (increased Wnt3a and Wnt7a,
decreased Dkk1) augments medial nu-
clear β-catenin accumulation, alkaline
phosphatase activity, and osteogenic
differentiation. The mural CVC, a
macrovascular myofibroblast related to
the microvascular pericyte, is thought to
be the resident osteoprogenitor. Stro-
1 (Collett et al, 2005) and adventi-
tial Sca1+ mesenchymal progenitors con-
tribute to medial and intimal disease pro-
cesses, and can undergo osteogenic dif-
ferentiation in response to BMP2/Wnt
signaling. However, the lineage relation-
ship between Sca1+ progenitors and the
CVC is currently unknown; speculation
based on studies of aortic mesoangioblast
development suggests that CVCs arise
from Sca1+ cells (Esner et al, 2006).
It remains possible that the osteogenic
potential of vascular progenitors is pro-
grammed within the adventitia but is
elaborated only when these progenitors
migrate with the vasa into the tunica me-
dia (Hu et al, 2004; Zemecke et al, 2005).
This model was first hypothesized in di-
abetic pathology; it is not possible to
exclude a similar mechanism in sponta-
neous calcification (Fig. 5.2).
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Aim of the Thesis
The existence of a capillary-rich vas-
culogenic zone has been identified in
adult human arteries; in this area it
has been postulated that MSCs may be
present amidst the endothelial progeni-
tors and hematopoietic stem cells (Zen-
gin et al, 2006). This hypothesis is
supported by several studies claiming to
have found the in vivo reservoir of MSCs
in post-natal tissues (da Silva Meirelles
et al, 2006 and 2008). Growing evi-
dence does indeed indicate a developmen-
tal relationship between pericytes and
MSCs (da Silva Meirelles et al, 2008; Do-
herty et al, 1998; Farrington-Rock et al,
2004; Covas et al, 2008; Crisan et al,
2008); moreover, it has been suggested
that pericytes may represent the MSC in
situ counterpart. The presence of mul-
tipotent progenitors is not restricted to
microvasculature; vascular wall resident
MSCs have already been isolated from
human large vessels such as the adult
thoracic aorta (Pasquinelli et al, 2007 a),
pulmonary artery (Hoshino et al, 2008),
saphena (Covas et al, 2005) and umbili-
cal veins (Covas et al, 2003).
We have first demonstrated that the
thoracic aorta harvested from multiorgan
donors yields MSCs endowed with angio-
genic ability (Pasquinelli et al, 2007 a);
now, we investigate whether embryonic-
like cells may persist in the adult life and
whether, according to the embryologi-
cal development of the aorta, MSCs may
reside in more proximal and peripheral
arterial segments collected from healthy
donors as well. Thus we evaluated stem
cell properties of VW-MSCs, i.e. the ef-
flux ability of DNA-binding dye Hoechst
33342, the clonogenicity and the ability
of growth as spheroids under appropri-
ate culture conditions and their multipo-
tency. Furthermore, we assessed an in
vivo pivotal study in order to evaluate
the neoangiogenic ability of vascular wall
derived MSCs and their behaviour in a
murine model of hindlimb ischemia.
Due to multipotency, VW-MSCs may
participate not only in physiological re-
newal, providing rapid targeted rescue
for regeneration after injury by giving
rise to new ECs and SMCs, but also in
pathological conditions. The vascular
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wall is one of the most frequent loca-
tion of pathological insults in humans;
the atherosclerosis is the major disease of
the arterial wall, but also calcifications
are diffuse. The mechanisms determin-
ing the development of arterial calcifi-
cation remain largely unexplored. Sev-
eral models have been proposed among
which the active contribute of pluripo-
tent arterial cells named calcifying vas-
cular cells. We focused our attention on
a less known pathology, the Mo¨nckeberg
sclerosis, an asymptomatic arterial calci-
fication which is often confused with end
stage atherosclerosis. It is no widely ac-
cepted that atherosclerotic calcification
and Mo¨nckeberg sclerosis have two dis-
tinct identities and consequently two dif-
ferent etiology (Doherty et al, 2004). On
the basis of our and other studies, we re-
tain that calcification of the medial layer
of artery wall arises independently from
atherosclerosis and VW-MSCs could play
an important role in the onset of the cal-
cification.
Thus, we studied a wide series of
human adult femoral arteries collected
from healthy multiorgan donors which
were examined in Light Microscopy (LM)
on Hematoxilin-Eosin (H-E) sections to
evaluate the presence of heterotopic calci-
fication and quantify this anomalous phe-
nomenon in healthy population. More-
over, we recovered personal and clini-
cal data from each donors in order to
find or exclude an eventual correlation
between the Mo¨nckeberg sclerosis and
the commonly recognized risk factors of
atherosclerosis such as diabetes, hyperc-
holesterolemia, tabagism, and hyperten-
sion. Furthermore, we have investigated
osteogenic ability of progenitors cells iso-





7.1 Arterial samples and vascular
niche characterization in im-
munohistochemistry
Fresh vascular samples were harvested
from heart-beating multiorgan donors;
the mean donor age was 39 years; 2
were females and 6 males. After pro-
curement and decontamination, the arte-
rial segments were fixed in buffered for-
malin, dehydrated and paraffin embed-
ded. Four-µm-thick sections were used
for immunohistochemical studies to lo-
calize VW-MSCs in situ involved into
vascular wall remodeling using antibod-
ies (Abs) directed against molecules com-
monly expressed by SCs. The slides were
processed according to the non-biotin-
amplified method with kit reagents (No-
voLinkTM Polymer Detection System,
Novocastra Laboratories Ltd., Newcastle
Upon Tyne, United Kingdom). Briefly,
sections of vessels were deparaffinated,
rehydrated through decreasing concen-
trations of ethanol (from 100% to 70%)
and rinsed in distilled water. Then, the
specimens were subjected to an antigen
retrieval treatment to enhance antigenic-
ity and allow epitope unmasking with
citrate buffer pH 6.0 at 120oC, 1atm for
21 minutes. After cooling and wash-
ing, the endogenous peroxidase activity
of the tissue was quenched for 10 min-
utes at room temperature (RT) with 3%
hydrogen peroxide solution in absolute
methanol in the dark. After washing
with Tris Buffered Saline (TBS) 1X, the
slides were blocked with NovocastraTM
Protein Block for 5 minutes in a wet
chamber to reduce the non-specific bind-
ing of primary antibody and polymer
reagent and rinsed twice with TBS 1X.
Successively, the samples were incubated
with primary antibodies diluited in 1%
Bovine Serum Albumin (BSA) in Phos-
phate Buffer Saline (PBS) over night
(o.n.) at 4degC. Vascular tissue sections
were stained using monoclonal antibodies
(moAbs) against Oct-4 (1:100, Chemicon
Int, Tamecula, CA, USA), Stro-1 (1:100,
R&D System, Milano, Italy), Sca-1 (1:10,
Cederlane Laboratories, Hornby, On-
tario, Canada), Notch1 (1:50, clone c-20,
SantaCruz, CA, USA). ASMA (1:9000,
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clone 1A4, Dako cytomation), CD34
(1:80 clone QBEnd-10, Dako), CD45
(1:600, clone 2B11+PD7/26, Dako),
CD68 (1:200, clone PG-M1, Dako), S-
100 (1:5000, Dako), CD117 (1:100, Dako
), ki-67 (1:200, clone MM1, Novocastra).
After washing, the slides were further
incubated for 30 minutes at RT with
NovocastraTM Post Primary Block to
enhance penetration of the next poly-
mer reagent, rinsed in TBS 1X and after
that incubated with NovoLinkTM Poly-
mer for 30 minutes at RT. After wash-
ing, the enzyme activity was visualized
with 3,3-diaminobenzidine (DAB), as
substrate, prepared from NovocastraTM
DAB Chromogen and NovoLinkTMDAB
Substrate Buffer, rinsed in distilled water
to stop the reaction and counterstained
with Gill’s hematoxylin. Subsequently,
the samples were dehydrated, cover-
slipped and viewed in a light microscopy
using the Image-Pro Plus R⃝ 6 software
(Media Cybernetics, Inc., Bethesda, MD,
USA). Images were digitalized through a
video camera (JVC 3CCD video camera,
KY-F55B, Jokohama, Japan) connected
with a Leitz Diaplan light microscope
(Wetzlar, Germany). Original images
were taken at 10X. Negative controls
were performed by omitting the primary
antibodies.
7.2 Progenitor cells isolation, cell
culture and flow cytometry
characterization
Cell isolation. Fresh arteries were
furnished by operating room of Vascular
Surgery of the S.Orsola-Malpighi Gen-
eral Hospital of Bologna for the vascu-
lar stem cells isolation. Each segment
was minced at approximately 5-cm-long
pieces, longitudinally cut, providing an
exposed surface area measuring about
25-30 cm2 and washed with saline solu-
tion under a laminar flow. The harvested
homograft segments were mechanically
minced with a scraper and enzymatically
digested with 0.3mg/ml liberase type II
(Roche, Milan, Italy) in DMEM serum
free (Lonza, Basel, Switzerland) for 30
minutes at RT. The sample was subse-
quently incubated with the same concen-
tration of Liberase type II at 37oC in 5%
CO2 humified atmosphere for other 30
min and subsequently at 37oC for other
4 hours using a rotor apparatus. Af-
ter digestion, the homogenate was re-
covered, filtered through a 100-70-40-µm
nylon mesh cell strainer (Becton Dick-
inson; Franklin Lakes, NJ), pelleted,
counted with Neubauer hemocytometer
and seeded at 1x106/cm2 on collagen-I
coated 12-well plates with DMEM sup-
plemented with 20% of heat inactivated
FBS (Lonza) and antibiotics (100 U/ml
penicillin and 100 µg/ml streptomycin)
and subsequently incubated at 37oC in
a humified atmosphere with 5% CO2.
Nonadherent cells were removed after
72 hours by washing with PBS. Cul-
ture media was changed every 3 days un-
til testing. When cells were near con-
fluence (approximately 1-2 weeks), they
were detached with 0.25% trypsin-EDTA
(Sigma, Milan, Italy), replated at a den-
sity of 5.000-6.000 cells per cm2 of sur-
face area as passage 1(P1), maintained in
DMEM supplemented with 10% FBS and
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subcultured for expansion and in vitro
analysis.
Immunophenotyping. Flow cy-
tometry analysis was performed to assess
the cell phenotype of VW-MSCs at pas-
sage 3-5 using the following MoAbs: anti-
CD29-fluorescein isothiocyanate (FITC),
CD31-phycoerythrin (PE), CD34-PE,
CD146-PE, CD44-FITC, CD45- allophy-
cocyanin (APC), CD73-FITC, CD90-
phycoerythrin-cyanine 5 (PC5), CD105-
PE, CD166-PE (all from Beckman
Coulter, Fullerton, CA, USA), von
Willebrand Factor (vWF, clone F8/86,
Dako Cytomation, Glostrup, Denmark),
STRO-1 (clone STRO1, R&D Systems),
Notch-1 (clone C-20, Santa Cruz Biotec-
nology), Oct-4 (clone C-10, Santa Cruz
Biotecnology). The following secondary
MoAbs were used after cell staining
with unlabeled primary MoAbs: anti-
mouse IgG-APC (Beckman Coulter),
anti-rabbit IgG-FITC (Dako Cytoma-
tion). To reveal vWF and Oct-4, the
cells were fixed and permeabilized with
the Intrapep Kit (Beckman-Coulter) and
subsequently incubated with anti-mouse
IgG-FITC (Dako Cytomation). Nega-
tive controls were performed using appro-
priate conjugated irrelevant antibodies.
Samples were analyzed using a Cytomics
FC500 flow cytometer equipped with two
lasers (Beckman Coulter). Results were
analyzed using the CXP Software (Beck-
man Coulter, Fullerton, CA, USA).
Hoechst SP labeling. To inves-
tigate the side population phenotype
among VW-MSC populations, cells at
3-5 passages were labeled with Hoechst
33342. Briefly, cells were suspended
in room-temperature Hanks’ balanced
saline solution containing 2% fetal bovine
serum and 2 mM HEPES buffer at 5x106
cells per milliliter. Cells were prewarmed
to 37oC, and Hoechst 33342 added to a
final concentration of 5µg/ml. Cells were
incubated for 90 minutes, centrifuged,
and resuspended in cold buffer at 5x106
per milliliter. Cells were then kept on ice
and analyzed within 6 hours of labeling.
Propidium iodide was added to the cells
at 2 µg/ml immediately prior to analysis.
For some experiments, cells were prein-
cubated with the ABCG2 inhibitor ver-
apamil (100µmol/L) at 37oC for 30 min-
utes prior to Hoechst 33342 addition.
7.3 Stemness analysis
7.3.1 Bell shaped nuclei
Recent studies have reported that
leukemic or normal colonic embryonic-
like stem cells have a peculiar bell-shaped
nuclear morphology reflecting specific
stem cell division (Kroschinsky et al,
2008; Gostjeva et al, 2006); accord-
ingly, we investigated whether this fea-
ture might also be present in VW-MSCs.
To address this issue, all vascular popu-
lations were recovered at passage 4 and
plated at 3x103/cm2 on collagen-I coated
slide chambers (BD Labware, Franklin
Lakes, NJ, USA); cells were fixed in 2%
paraformaldehyde for 4 minutes at RT,
and mounted with Pro-long anti fade
with DAPI mounting solution (Molecular
Probes, Milan, Italy). Samples were ob-
served under a Leica fully automated in-
verted fluorescence microscope DMI6000
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B using a DAPI filter (Leica Microsys-
tems, Milan, Italy). At least 200 nu-
clei/sample were counted on a minimum
of 10 HPF. The percentage/sample of
cells having bell-shaped nuclei was de-
termined by counting the total number
of bell shaped nuclei and calculating the
percentage of cells with this characteris-
tic out of the total number of counted
nuclei. The count was performed inde-
pendently by two operators on the same
samples and then a mean of the individ-
ual results was calculated.
7.3.2 Clonogenic Assay
To establish colony-forming units
cells, VW-MSCs at passage 5 were plated
in cell culture Petri dishes (Corning, NY,
USA) coated with collagen I (Sigma) at
approximately 1 cell to 10 cells/cm2 and
left growing till 100-150 cells per colony
was achieved. Colony growth was visual-
ized directly on plate after crystal violet
staining; culture dishes were washed with
PBS to remove growth medium; then
colonies were fixed overnight in buffered
formalin, stained with 0.1% crystal violet
in 20% methanol for 30 minutes at RT,
washed with distilled water, dried and
observed. The percentage of clonogenic
cell subsets was estimated by counting
colonies derived from all seeded cells.
7.3.3 In vitro spheroid formation
and characterization: immunoflu-
orescence, molecular and electron
microscopy analysis
Stem cell ability to form spheres is
a well known acquisition (Ingram et al,
2005). To determine whether VW-MSCs
had this growth capacity, adherent VW-
MSCs at passage 5 were suspended in
culture medium and plated at 2x104
cells/well in ultra-low attachment 24-
well plates. After a few days, numer-
ous spheres were observed under light
microscopy. The spheres were recov-
ered and processed for immunofluores-
cence microscopy (IF), transmission elec-
tron microscopy (TEM) and RT-PCR
gene expression analysis.
Immunofluorescence analysis.
Single spheres were embedded in a
2% agar gel, mounted on a cork dish
with a small amount of OCT mount-
ing medium and frozen in liquid isopen-
tane cooled in liquid nitrogen at -160oC.
Frozen blocks were stored at -80oC un-
til use. Immunofluorescent staining was
performed on 6 /mum-thick sections cut
with a cryostat at -20oC. Frozen sec-
tions were dried at RT and fixed in cold
acetone. After a second drying step,
the sections were washed and incubated
with 1% BSA in PBS to block unspe-
cific reactive sites. Immunostaining was
performed by labeling the samples with
MoAbs against CD133 (1:80, Miltenyi
biotec, Bergisch Gladbach, Germany),
CD34 (clone QBEND-10, 1:80, Dako
Cytomation), c-kit (1:200, SantaCruz
Biotechnology) Stro-1 (1:100, R&D Sys-
tem), Sca-1 (1:10, Cederlane Laborato-
ries), Oct-4 (1:100, Chemicon), CD44
(clone G44-26, 1:50, BD), Notch1 (1:50,
clone c-20, SantaCruz) for 45 minutes at
37oC and then incubating with FITC-
conjugated polyclonal rabbit anti-mouse
immunoglobulins for 45 minutes at 37oC.
Finally coverslips were mounted with
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Pro-long anti fade with DAPI mount-
ing solution and the samples were ob-
served under a Leica fluorescence micro-
scope DMI6000 B using appropriate fil-
ters. Original images were taken at 10X.
For negative control, the sections were
processed omitting the primary antibody,
and no signal was detected.
Transmission electron microscopy.
The subcellular characteristics of cells
aggregated into spheroids were investi-
gated by TEM. The recovered samples
were pelleted, fixed in 2.5% phosphate-
buffered glutaraldehyde for 24 hours at
4oC, followed by post fixation with 1%
buffered osmium tetroxide (OsO4) for 1 h
at RT. They were then washed with 0.15
mol/L phosphate buffer, dehydrated in a
graded series of ethanol and embedded in
epoxy resin; thin sections were counter-
stained with lead citrate and uranyl ac-
etate and then observed with a transmis-
sion electron microscope Tecnai 12 (FEI
Company, Milano, Italy).
Scanning electron microscopy.
To analyze the three-dimensional ar-
chitecture of spheres, they were seeded
on polylysin-coated glass coverslips for 6
hours and then processed for SEM analy-
sis. The adherent spheroids were washed
with 0.15 mol/L phosphate buffer, pH
7.4, and then fixed with 2.5% phosphate
buffered glutaraldehyde (TAAB Labora-
tories, England, UK) pH 7.4 for 24 hours
at 4oC. Afterwards, the spheres were
washed and post fixed in 1% phosphate
buffered (OsO4) , rinsed in distilled wa-
ter and dehydrated in a graded series of
ethanol. To dry the samples, they were
first incubated in a solution of 50% abso-
lute ethanol/50% hexamethyldisilazane
(HMDS) (Fluka Analytical, Sigma) and
then in pure HMDS; samples were dried
at RT. To observe the samples, they were
mounted on aluminium stubs with sil-
ver paste and coated with a 10 nm thick
gold film in a sputtering device (Balz-
ers Union FL9496, Furstentum, Liechten-
stein); samples were finally observed with
a Philips SEM 505 (FEI Company) at 15
kV.
RT-PCR Gene expression analysis.
VW-MSCs isolated from human TA
constitutively expressed the embryonic
stem cell marker Oct-4, molecules in-
volved in stem cell critical regulatory
pathways, i.e., c-kit, BCRP-1, BMI-1,
and KDR, as well as, to a lower ex-
tent, hematopoietic stem cell transcripts,
e.g., CD133. We also investigated which
regulation pathways are predominantly
expressed in stem cell forming spheres
among c-kit, Notch-1, BCRP-1, BMI-1,
SOX-2, Oct-4, CD133 and KDR genes.
Total RNA was extracted from spheroids
using the RNA extracting reagent TRI
reagent (Ambion Applied Biosystems,
Austin, TX, USA, www.ambion.com) ac-
cording to the manufacturer’s instruc-
tions. Reverse transcription reactions
were performed in a 40 µl volume with 4
µg of total RNA and the RT-PCRs with
1µl of this solution. PCR primers are
listed in Table 7.1 and were purchased
from Invitrogen; RT reagents were fur-
nished by Ambion Applied Biosystems
and PCR reagents by Qiagen (Milan,
Italy). The PCR products were sepa-
rated by electrophoresis on a 2% agarose
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Table 7.1. Primers for reverse transcription and polymerase chain reaction.
GENE Primers Sequence Amplicon length (bp) TaoC
Oct-4 REV 5’-CCACATCGGCCTGTGTATAT-3’ 380 60
FW 5’-CTCCTGGAGGGCCAGGAATC-3’
BMI-1 REV 5’-CATTGCTGCTGGGCATCGTAAG-3’ 369 62
FW 5’-GGAGACCAGCAAGTATTGTCCTTTTG-3’
BCRP-1 REV 5’-CTGAGCTATAGAGGCCTGGG-3’ 652 60
FW 5’-GTTTATCCGTGGTGTGTCTGG-3’
CD133 REV 5’-GTACAACACTACCAAGGACAAGGCGT-3’ 337 62
FW 5’-CTGGGGCTGCTGTTTATTATTCTG-3’
KDR REV 5’ TTTGTCACTGAGACAGCTTGG-3’ 555 62
FW 5’ TATAGATGGTGTAACCCGGA-3’
c-kit REV 5’ CATACAAGGAGCGGTCAACA-3’ 275 57
FW 5’ GTCTCCACCATCCATCCATC-3’
SOX-2 REV 5’-GCGCCGCGGCCGGTATTTAT-3’ 208 60,5
FW 5’-ACCGGCGGCAACCAGAAGAACAG-3’
Notch-1 REV 5’-TGGCATCAGCTGGCACTCGTCC-3’ 496 62
FW 5’-CCGGCTGGTCAGGGAAATCGTG-3’
β2 µglobulin REV5’-ATCTTCAAACCTCCATGATG-3’ 114 58
FW 5’-ACCCCCACTGAAAAAGATGA-3’
ASMA REV 5’- GTGATCTCCTTCTGCATTCGGT-3’ 372 60
FW 5’- CTGAGCGTGGCTATTCCTTC-3’
CALP2 REV 5’-GCAGGTCTGAGGGTCTGAAG-3’ 470 60
FW 5’-CCAGTCAACCAAGGGTCTGT-3’
CALD REV 5- GCTGCTTGATGGGTCGATTTGA-3’ Low: 744 60
FW 5’- GTCACCAAGTCCTACCAGAAGA-3’ High: 1508
gel with 1x Tris-acetate-EDTA buffer,
stained with ethidium bromide and pho-
tographed under ultraviolet light.
7.4 Multilineage differentiation
potential
7.4.1 Adipogenic commitment: in
vitro procedure, Oil red O staining
and TEM analysis
Twenty thousand cells/cm2 were cul-
tured for 3 weeks in adipogenic dif-
ferentiation medium; DMEM was sup-
plemented with 10% FBS, 0.5 mmol/L
isobutyl-methyl xanthine (IBMX), 200
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µmol/L indomethacin, 1µmol/L dexam-
ethasone and 20 µg/mL insulin (all
reagents were from Sigma). Induction
Medium was replaced every 2-3 days and
alternated with maintenance medium
(DMEM 10% FBS and 20 µg/mL in-
sulin). Negative controls were cultured
in standard condition (DMEM plus 10%
FBS).
Morphological features of adipogenic
differentiation were observed by inverted
light microscopy and TEM, whilst the cy-
toplasmic presence of lipid droplets was
assessed by Oil Red O staining. For
TEM analysis, cells were gently washed
with 0.15 mol/L phosphate-buffer, fixed
directly in plates with 2.5% phosphate-
buffered glutaraldehyde for 10 min at RT,
scraped, collected and centrifuged for 10
min at 1800 rpm. Pellets were left in
2.5% phosphate-buffered glutaraldehyde
for 24 hours at 4oC and processed as de-
scribed above. For Oil Red O staining,
cells were fixed in 10% neutral buffered
formalin, rinsed in 60% isopropanol and
then stained with Oil red O solution for
30 min at RT. Cells were rinsed in 60%
isopropanol again, lightly stained with
hematoxylin, rinsed with distilled wa-
ter, and mounted in aqueous mounting
medium.
7.4.2 Osteogenic commitment:
in vitro procedure, von Kossa stain-
ing and TEM analysis
Five thousand cells/cm2 were cul-
tured in DMEM supplemented with 15%
FBS, 10 mmol/L β-glycerophosphate,
0.17 µmol/L ascorbic acid, and
0,1µmol/L dexamethasone (Sigma) for
3-4 weeks; the medium was replaced ev-
ery 2-3 days. Controls were cultured in
basal medium (DMEM with 10% FBS).
Osteogenic differentiation was assessed
by TEM (as described above) and by
Von Kossa stain to identify calcium salt
extracellular deposition. Briefly, cells
were fixed in 10% neutral buffered forma-
lin, washed in distilled water and incu-
bated in 1% silver nitrate solution for 20
min under ultraviolet light. After several
washing steps with distilled water, sam-
ples were incubated for 5 min at RT in a
solution of 5% sodium thiosulfate, rinsed
in distillated water, counterstained with
1% nuclear fast red solution, dehydrated
and mounted using a permanent mount-
ing medium (Canadian Balsam, Sigma).
7.4.3 Chondrogenic commit-
ment: in vitro procedure, Type II
Collagene IHC and TEM analysis
Two hundred and fifty thousand cells
were gently pelleted in 15 ml polypropy-
lene tubes (Corning) and cultured for
three weeks in complete chondrogenic
differentiation medium (Lonza) contain-
ing 10 ng/ml TGFβ3 (Lonza) by feeding
twice a week.
Controls were cultured in chondro-
genic differentiation medium without
TGFβ3. To verify VW-MSCs’ chon-
drogenic differentiation potential, pel-
lets were processed for TEM (as de-
scribed above) and for histological anal-
ysis to evaluate collagene type II synthe-
sis. Briefly, pellets were formalin-fixed
and paraffin embedded; 3 µm-thick sec-
tions were stained with hematoxilyn and
eosin and examined at light microscopy.
To examine the expression of type
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II collagen, dewaxed sections were di-
gested with pepsin (0.5 mg/ml Tris-
HCl, pH 2.0) for 15 at RT; endogenous
peroxidase was blocked with absolute
methanol containing 1.5% H2O2. Sec-
tions were incubated with mouse MoAb
anti-human collagen type II (1:200 in
1% BSA-PBS; Chemicon Int) in a wet
chamber at 4oC overnight. The antigen-
antibody reaction was revealed using the
Novolink Polymer detection System (No-
volink) according to the manufacturer’s
protocol. The signal was developed with
diaminobenzidine cromogen and sections
were counterstained with hematoxylin.
Negative controls were performed by
omitting the primary antibody.
7.4.4 Leiomyogenic commit-
ment: in vitro procedure, IF and
gene expression analysis of smooth
muscle markers, TEM analysis
Three thousand five hundred
cells/cm2 were plated on Collagen I Bio-
coated culture six-well plates (BD) in
SmGM-2 (Lonza). After 24 hours, the
medium was changed for differentiation
medium containing SmGM-2 plus 10
ng/ml TGF-β1 (Sigma) and 5 ng/ml
PDGF-BB (Sigma). Cells were cultured
for 14 days, feeding the medium every
3 days. Cell controls were cultured in
SmGM-2 without additional growth fac-
tors.
To evaluate smooth muscle marker
expression, IF, RT-PCR and TEM anal-
ysis were performed.
VW-MSCs were washed with PBS,
fixed and permeabilized with 2%
paraformaldehyde 0,1% TRITON in PBS
for 4 min at RT. Aspecific antibody
binding sites were blocked by incubat-
ing with 1% BSA in PBS for 30 min
at RT. Cells were incubated over night
at 4oC in a humidified chamber with
the following anti human mouse mono-
clonal antibodies (alpha smooth muscle
actin, 1:9000, clone 1A4; H-caldesmon,
clone h-CD, 1:75; calponin, clone CALP,
1: 40; vimentin, 1: 260, clone V9;
all purchased from Dako Cytomation).
Antigen-antibody reactions were labeled
with rabbit fluorescein-conjugated anti
mouse IgG (Dako Cytomation) for 45
min at 37oC. After several washes, sam-
ples were mounted and nuclei counter-
stained with Pro long antifade reagent
with DAPI (Molecular Probes). Nega-
tive controls were done by omitting the
primary antibodies.
The expression of smooth muscle spe-
cific genes, such as alpha-smooth mus-
cle actin (ASMA), calponin 2 (CALP2)
and caldesmon (CALD), was evaluated
by RT-PCR. Total RNA was extracted
from induced and non induced cells and
reverse transcription was performed as
described above. The primers listed in
Table 7.1 were selected for amplifica-
tion using GoTaq Hot Start Polymerase
(Promega Corporation, USA); for detec-
tion of β2-µglobulin, ASMA, CALP2,
and CALD, the following parameters
were used: 94oC for 3 min and then 30
cycles of 40 sec at 94oC for denaturation,
30 sec at 60oC for annealing, 90 sec at
72oC for polymerization, and 5 min at
72oC. The PCR products were separated
by electrophoresis on a 1.5% agarose
gel with 1X Tris-acetate-EDTA buffer,
stained with ethidium bromide and pho-
tographed under ultraviolet light.
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TEM analysis of VW-MSC leiomyo-
genic differentiation was performed as de-
scribed above.
7.5 Experimental model of hind
limb ischemia and cell therapy
Ten Male CD1 Foxn1nu/nu mice
(Charles River Laboratories, Wilming-
ton, Mass) were housed at constant
RT (24 ± 1oC) and humidity (60 ±
3%). At 6-week-old, under the effect
of 2,2,2-tribromoethanol anesthesia (880
mmol/kg body weight intraperitoneally;
Sigma), the mice underwent unilateral
limb ischemia on the left limb by liga-
tion of the femoral artery. Subsequently,
2x104 TA-MSCs (passage 4) resuspended
in 30 µl of medium or vehicle (DMEM, 30
µl) were injected into 3 different points
of the ischemic adductor muscle (n. 5
mice per group).
7.5.1 Assessment of blood flow
recovery, neoangiogenesis and ther-
apeutic potential of VW-MSCs
Eco color Doppler. Blood flow re-
covery was followed up by laser Doppler
flowmetry measurements. At 7 and 14
days postischemia, the superficial blood
flow (BF) of both feet and limb was mea-
sured in anesthetized mice by color laser
Lisca Doppler (Peri-med AB, Ja¨rfa¨lla,
Sweden), and the ratio of perfusion be-
tween ischemic to nonischemic limb and
foot was calculated.
Immunohistochemistry analysis.
Two weeks after induction of hindlimb
ischemia, mice were euthanized and per-
fused with 4% formalin. Adductors and
gastrocnemii were excised from hischemic
and non hischemic limb and paraffin em-
bedded for immunhistochemical analysis.
Three µm sections of paraffin-embedded
muscles, harvested at day 14 after is-
chemia were processed for neoangiogene-
sis and immunohistochemical analysis as
described above.
Capillary density
The samples were stained with
isolectin B4 to recognize ECs; positive
capillaries were counted on the whole sur-
face of tissue sections and the results
were reported as numbers of capillaries
for square millimeters.
Hypoxia
Mice muscles were stained with HIF-
1α (1:4000, Novus Biological) to evalu-
ate the contribute of vascular progenitor
cells in ameliorating hypoxic conditions.
We calculated the percentage/sample of
HIF-1α positive cells comparing to the
total number of nuclei (positive and neg-
ative) on a minimum of 5 random HPF;
the fold change values were obtained by
the ratio between correspondent ischemic
and controlateral non ischemic muscles.
We followed the protocol described in 7.1
paragraph except for the antigen retrieval
performed microwave with TRIS-EDTA
(50mM-0,2mM) and the incubation with
primary antibody carried on for 90 min-
utes at RT.
Engrafment and differentiation in pre-
existing vessels
We evaluated the engrafment of
transplanted cells and the neovascular-
ization through specific anti-human mi-
tochondria stain (1:100, Chemicon) and
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anti-human CD34 stain (1:80, Dako Cy-
tomation). Furthermore we evaluated
the in situ level of VEGF (1:50, Abcam),
and muscle regeneration using a selective
anti mouse PAX7 (1:50,R&D System) in
order to quantify the satellite cells acti-
vation.
Statistical analysis
We performed statistical analysis on
all experiments. Values are presented
as mean ± SEM. Analyses were per-
formed with GraphPad Prism 4.0 soft-
ware (GraphPad Software, San Diego,
Calif). Statistical significance was as-
sessed by use of unpaired t test for com-
parison between 2 groups. For analysis
of blood flow recovery in which measure-
ments were repeated on the same subject
at different time points, repeated mea-
sures ANOVA was used, followed by Bon-
ferroni post hoc test. P < 0.05 was inter-
preted to denote statistical significance.
7.6 Femoral arteries collection,
classification and statistical
analysis
We evaluated the frequency of vascular
calcification on femoral artery tissue sec-
tions obtained from vascular segments
recovered by healthy multiorgan donors
and collected at Regional Cardio Vascu-
lar Tissue Bank in Bologna from January
2005 to March 2010. A small portion of
each sample was formalin fixed, paraf-
fin embedded, cutted with microtome
and processed for hematoxylin and eosin
staining. The sections were observed
at light microscope and the respective
donors were classified as “calcified” or
“non calcified” on the basis of the evi-
dence of calcification area in the tunica
media, a condition known as Mo¨nckeberg
Sclerosis. Successively we divided all
donors in different age classes and recov-
ered their clinical information concerning
diabetes, tabagism, hypercolesterolemia
and hypertension status in order to even-
tually correlate these clinical conditions
with the presence of vascular calcification
calculating the correspondent Odd Ratio
values.
7.7 Isolation, flow cytometry char-
acterization and osteogenic
commitment of calcifying vas-
cular cells
After light microscopy analysis, we se-
lected one calcified femoral segment un-
suitable for long term banking and used
it for VW-MSCs isolation as previously
described (paragraph 7.2). At 3rd pas-
sage VW-MSCs were processed for flow
cytometry analysis to evaluate the ex-
pression of mesenchymal (CD44, CD90,
CD166,CD105, CD166, CD29) endothe-
lial (CD31, CD34, KDR) and stemness
(Oct-, Stro-1, Notch-1, Sca-1) markers.
Furthermore, VW-MSCs derived
from calcified vessel (called cVW-MSCs)
were taken at passages 3 and differenti-
ated towards osteogenic lineage accord-
ing to a consolidate protocol described
by Alviano et al (Alviano et al, 2007).
In vitro osteogenesis was verified with
von Kossa stain and TEM analysis to
evaluate the presence of calcium deposit.
Furthermore, the results were compared
with those obtained from osteogenic com-
mitment of VW-MSCs derived from non
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calcified vessels (called ncVW-MSCs).
7.8 Immunohistochemistry assay
and statistical analysis
To localize in situ the osteoprogenitor
cells, we performed an immunohisto-
chemistry (IHC) analysis on 5µm-thick
sections of vessels against one of the mas-
ter transcriptional factors regulating os-
teoblat differentiation such as Osterix
(Osx) using the polyclonal antibody Osx
(1:100, Abcam, Cambridge, UK). The
antigen-antibody reaction was revealed
using Novolink Polymer detection Sys-
tem (Novolink, New Castle, UK) follow-
ing the manufacture protocols. Samples
were observed under a Leitz Diaplan light
microscope (Wetzlar, Germany) and pos-
itive cells were counted both in tunica
media and in tunica adventitia on a min-
imum of 10 HPF. The percentage of Osx
positive cells was calculated on the total
number of cells in each HPF. Non para-
metric one-way ANOVA (Kruskal-Wallis
test) was used to detect differences be-
tween tunica media and adventitia scores
for Osx positivity and clinical condition
such as hypertension or absence of risk
factors; analyses were performed using




Multidistrict human mesenchymal vascular cells:
stemness characteristics and pluripotency
8.1 Arterial samples and vascular
niche characterization in im-
munohistochemistry
More recently our group described the
presence of VW-MSCs in normal hu-
man adult thoracic aortas. After cryop-
reservation, the vast majority of VWCs,
i.e. ECs and SMCs, were irreversibly in-
jured (Pasquinelli et al, 2006). Inter-
estingly the only cells in the cryopre-
served arterial wall which still remained
viable after 4 days of organ culture were
capillary structures located in between
the media and adventitia layers; there-
fore microvascular stress-resistant cells
CD34+/CD31- are present in this arte-
rial zone. This area was richly endowed
with highly expressing Human Leuko-
cyte Antigen class I antigen small cal-
ibre vessels (Pasquinelli et al, 2007 b),
and therefore could act as a strategic
area for the recruitment of blood circu-
lating cells. In accordance with this we
observed the presence of bone marrow-
derived CD45+ mononuclear cells. Ad-
ditional experiments on femoral arter-
ies confirmed these results and also re-
vealed the presence of CD68+ and S-
100+ perivascular cells representing res-
ident macrophages and dendritic acces-
sory cells. Moreover, this area has cer-
tain characteristics — e.g. discrete mor-
phology, a strategic location at the inter-
face between media and adventitia lay-
ers, heterogeneous and complex cell com-
position, an unexpectedly elevated cell
proliferation under normal conditions,
selective localization of cells expressing
the stem cell surface molecule c-kit —
which makes it unique in the arterial wall
and consistent with a nichelike function
(Fig. 8.1).
To further strengthen the concept
that in vivo this area exerts a niche-like
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Figure 8.1. Vasculogenic niche of the human femoral artery.
function, we accomplished an immuno-
histochemical study of stemness mark-
ers on arterial wall sections for each dis-
trict (AA, TA, FA). Regardless of vas-
cular segments, we found that Notch-1,
Stro-1 and Sca-1 positive cells were dis-
tributed along the previously described
vasculogenic-niche; also small, rounded
and Oct-4 positive cells appear to localize
in this area (Fig. 8.2).
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Figure 8.2. Representative picture of perivascular-niche.
8.2 Progenitor cells isolation, cell
culture and flow cytometry
characterization
From anatomically distinct segments we
succeeded in isolating cells with morpho-
logical and immunophenotypical proper-
ties of MSCs; primary cell cultures were
established from two AA, four TA and
three FA, thus demonstrating that MSC
populations are present in arteries and
have different in vivo extents and ar-
chitecture, i.e., an elastic and muscu-
lar typology. Depending on the starting
amount of arterial tissue used to estab-
lish the cultures, conluence was reached
within 5 days. The cells were spindle-
shaped and had a tendency to grow in
a whorled pattern (Fig. 8.3). No sig-
nificant differences, as judged by mor-
phological, immunophenotype and func-
tional analysis, were observed among cul-
tures generated from arterial segments
leading to different anatomical districts
or architectures; because the amount of
tissue available for the study varied con-
siderably, comparative analysis to estab-
lish MSC yield differences among arterial
sources was not possible.
Regardless of the vascular source,
cells derived from the human arterial wall
had an immunophenotype profile consis-
tent with that of MSCs; examples of
flow cytometry surface molecule single
analysis are shown in Fig. 8.4. All
the populations expressed typical mes-
enchymal antigens such as CD29, CD44,
CD90, CD73, CD105, and CD166; on the
contrary hematopoietic lineage (CD45),
hematopoietic progenitor (CD34) and
endothelial cell (CD31, vWF, CD146)
markers were negative. Stemness mark-




Figure 8.3. W-MSCs morphology at 4th culture day (left) and at 3rd
culture passage (right).
8.3 Stemness analysis
A defining property of stem cells is low
fluorescence after staining with Hoechst
33342. VW-MSCs were stained with
Hoechst 33342 in presence or absence of
verapamil and processed for flow cytom-
etry analysis. We found that approxi-
mately the 1% of all VW-MSCs posses
the SP phenotype; efflux of Hoechst
33342 dye was inhibited by verapamil,
confirming the specificity of the staining
(Fig. 8.5).
Other features of the more undiffer-
entiated stem cells are the presence of
bell-shaped nuclei and their clonogenic
ability, both features related to symmet-
ric divisions occurring during the cell
cycle. Under a DAPI filter, the to-
tal number of bell-shaped nuclei were
counted and later compared with the to-
tal number of seeded cells. Regardless
of the vascular source, we found that a
percentage ranging from 0.30 ± 0.05%
of VW-MSCs present bell-shaped nu-
clei (Fig. 8.6A), a morphological char-
acteristic of embryonic-like stem cells.
This result suggests that primary cul-
tures of VW-MSCs are heterogeneous
even though they present similar growth
and immunophenotypical characteristics;
as indicated by DAPI identification of
cells with bell-shaped nuclei, a small pro-
portion of hierarchically higher cells ex-
ists; this finding was confirmed by other
in vitro assays aiming to evaluate more
established stemness characteristics of
VW-MSCs.
To investigate the clonogenic ability
of VW-MSCs, single cells were seeded in
a 100 mm Petri dish via limited dilution.
At this low density culture condition we
noted that cells initially displayed a par-
ticular phenomenon known as shrink ef-
fect, a typical suffering response to non
optimal growing conditions; the cells ex-
hibited membrane wrinkling and flatten-
ing; only stress-resistant cells managed
to survive in such an unfavorable con-
test. We found that 0.36% ± 0,03% of to-
tal VW-MSCs retained a clonogenic abil-
ity in adult life (Fig. 8.6B and 8.6C);
again, the clonogenic assay shows that,
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Figure 8.4. Flow cytometry analysis of VW-MSCs immunophenotype.
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regardless of the arterial origin or similar-
ities in growth and immunophenotypical
characteristics, VW-MSCs are heteroge-
neous and contain a subset of more undif-
ferentiated cells according to the stage of
embryological development. This intrin-
sic ability is in agreement with current
views about the clonal origin of some dis-
eases like tumors.
When VW-MSCs were seeded in
ultra-low attachment plates, they formed
agglomerates that were able to gener-
ate growth-forming spheres (Fig. 8.6D).
Cells constituting spheres expressed stem
cell markers, including c-kit, Stro-1,
Notch-1, Sca-1, and mesenchymal mark-
ers such as CD44 as documented by
IF analysis (Fig. 8.6E), whereas they
were negative to hematopoietic progeni-
tor, CD133 and CD34 markers. Further-
more, RT-PCR analysis confirmed stem
cell gene expression and demonstrated
that at passage 5, VW-MSCs lose the
expression of BCRP-1 and BMI-1 previ-
ously described at passage 3 in thoracic
aorta MSCs (Pasquinelli et al, 2007 a),
whilst the expression of c-kit and Oct-
4 persisted during extended subculture
(Fig. 8.6F and 8.6G).
TEM analysis of spheres showed un-
differentiated cells with large, irregularly-
shaped nuclei, dispersed chromatin, and
prominent nucleoli; the cytoplasm con-
tained mitochondria and profiles of rough
endoplasmic reticulum which in some
cells were distended by the presence of
moderately dense material; in the in-
tercellular space we occasionally found
collections of extracellular membrane
vesicles and primary cilia documenting
intense extracellular membrane traffic;
primitive intercellular junctions were oc-
casionally seen and gap junctions as
Figure 8.5. Identification of arterial SP cells.
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Figure 8.6. Stemness characteristics of VW-MSCs.
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well; the outer cell layer had unex-
pectedly smooth surfaces with randomly
spaced long and thin floating filopodia
(Fig. 8.7).
SEM analysis demonstrated that the
spheres were round with diameters rang-
ing from 60 to 100 micron; on expand-
ing TEM observations, outer cells showed
cell membrane protrusions corresponding
to surface blebbing (Fig. 8.8).
8.4 Multilineage differentiation
potential
Cells were cultured under specific experi-
mental conditions and exhibited a similar
ability to differentiate along mesenchy-
mal lineages.
All VW-MSCs showed high adi-
pogenic potential, though this ability was
more intense when VW-MSCs were iso-
lated from thoracic aortas and femoral
Figure 8.7. TEM analysis of spheres.Abbreviation: primary cilium (PC); nucleus
(N) nucleoli (Nu), rough Endoplasmic Reticulum (rER); primitive intercellular
junction (J); extracellular membrane vesicles (V).
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Figure 8.8. SEM analysis of spheres.
arteries. VW-MSCs treated with adi-
pogenic media showed the presence of
multiple cytoplasm vacuoles that in-
creased in size and number with the time
of induction. Conversely, uninduced cells
retained their morphology and did not
display significant cytoplasm vacuoles.
As seen in Fig. 8.9, vacuoles stained in-
tensely with the lipid dye Oil Red O.
By TEM, VW-MSCs contained multiple,
confluent lipid droplets in the cytoplasm
and small dense mitochondria, besides an
elevated endocytic activity.
VW-MSCs also showed a good capac-
ity for chondrogenic differentiation; light
microscopy on high-density cell cultures
revealed that cells were embedded in an
abundant extracellular matrix; immuno-
histochemistry revealed the presence of
human type II collagen which is typically
found in joint cartilage. Ultrastructural
analysis confirmed the presence of abun-
dant extracellular matrix containing ma-
ture collagen fibers and proteoglycan par-
ticles in induced cells exclusively. Un-
like adipogenesis and chondrogenesis, the
osteogenic differentiation potential was
not so efficient. At light microscopy,
von Kossa staining showed a calcium-rich
mineralized matrix but the staining was
less diffusely distributed than expected.
However, TEM revealed multiple foci of
electron dense fibrillary deposits which
were decorated with needle-shaped hy-
droxyapatite crystals. Overall these re-
sults were illustrated in Fig. 8.9.
Regarding the leiomyogenic differen-
tiation potential, gene expression anal-
ysis showed increased levels of alpha-
Smooth Muscle Actin (ASMA) and High-
Caldesmon (H-CALD) genes compared
to controls. Again, stimulation with
TGF-β1 and PDGF-BB caused de novo
expression of the smooth muscle specific
marker calponin 2 (CALP2). By com-
paring smooth muscle marker expression
levels no significant difference was seen
among VW-MSCs deriving from vari-
ous arterial sources. TEM of induced
cells showed a myofibroblast phenotype;
the cells were spindle-shaped and con-
tained abundant peripherally arranged
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Figure 8.9. Multilineage potential of VW-MSCs.
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contractile filaments along with profiles
of rough endoplasmic reticulum; well-
organized fibronexus junctions were also
seen; control cells, in contrast, main-
tained an undifferentiated mesenchymal
phenotype (Fig. 8.10). Immunofluores-
cence analysis on induced and uninduced
cells confirmed RT-PCR results; in fact,
smooth muscle specific proteins were up-
regulated after leiomyogenesis induction
(Fig. 8.11).
Figure 8.10. Leiomyogenic differentiation of VW-MSCs. Abbreviations: Basal
Membrane (BM), Contractile Filaments (CF), Fibronexus (FN).
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Figure 8.11. Immunofluorescent analysis of leiomyogenesis.
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Role of vascular progenitor cells in therapeutic
angiogenesis
8.5 Blood flow recovery
The hind limb ischemia was successfully
reached and the intramuscular injection
of VW-MSCs did not cause neither ad-
verse reaction or weight loss in treated
animals. Eco Doppler analysis showed
that in this pivotal study cellular admin-
istration did not significantly accelerate
blood flow recovery in treated animals
compared to control one; however, as we
can see in Fig. 8.12, we could assist to
Figure 8.12. Blood flow recovery analysis.
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a slight ameliorating limb blood flow at
14 days in treated animals compared to
7 days postischemia whereas control ani-
mals showed a decline in limb blood per-
fusion. On the contrary, both at 7 days
and at 14 days after hind limb ischemia
we observed higher levels of foot perfu-
sion supported by cellular injection com-
pared to untreated group (Fig. 8.12).
8.6 Capillary density and Hypoxia
Eco color Doppler results were in line
with those obtained with immunohis-
tochemistry analysis of capillary den-
sity and hypoxia conditions of adductors
and gastrocnemii muscles. Indeed, we
found that capillary density was higher
in VW-MSC-injected than in vehicle-
injected muscles and this difference was
statistically significant in adductors. We
also evaluated hypoxic condition in mus-
cle tissues by counting HIF-1α positive
cells and fold change data reported in
Fig. 8.13 showed a remarkable reduc-
tion in hypoxic status presumably due to
VW-MSCs contribute.
8.7 Engraftment and differenti-
ation of transplanted VW-
MSCs into ischemic tissues
The most important end point of cell
therapy is the development of new ves-
sels in order to supply to defective or oc-
cluded vessels. Thus, we evaluated the
engrafment of human cells in pre-existent
Figure 8.13. Evaluation of muscles capillary density and hypoxic condition.
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vessels and the stem cells contribute in
neoangiogenesis in ischemic muscles. We
found that in adductors the 17 ± 1,6%
of total vessels contain well integrated
human cells, whereas in the gastrocne-
mii this percentage was lower 14 ± 6%.
This result was expected because VW-
MSCs were injected in adductors mus-
cles, but contemporary we assisted to
a migration of vascular cells in recalled
by local stimuli produced in functionally
compromised tissues. Furthermore we in-
vestigated the in vivo differentiation of
transplanted cells in endothelial cells and
we observed that the 16,5 ± 5% of total
vessels contained human CD34 positive
cells in the adductors muscles, whereas in
the gastrocnemii the percentage was 20
± 0,1%. We do not know whether these
were functional vessels (Fig. 8.14).
8.8 Supporting role of trans-
planted cells
Numerous experimental evidences
demonstrated that cellular therapy is not
only efficient in term of neovascularisa-
tion, but also support local cells/tissues
to repair their damages by synthesis of
growth factors. We supposed that vas-
cular progenitor cells could contribute in
augmenting the VEGF availability and
Figure 8.14. Engrafment and differentiation of transplanted human vascular cells.
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Figure 8.15. In situ evaluation of VEGF levels.
the muscle regeneration, thus we quan-
tified this contribute evaluating muscle
fibers synthesis of VEGF and Satellite
Cells activation by counting PAX7 posi-
tive cells. We found that adductors and
gastrocnemii muscles exhibited opposite
behavior; indeed, the VEGF was much
more expressed in VW-MSCs-injected
adductors compared to vehicle-injected
one and, at the same time, to gastroc-
nemii of treated animals. Conversely,
gastrocnemii of control group had more
VEGF level compared to the VW-MSCs-
injected muscles. These results could ex-
plain the more elevated capillary density
observed in adductors muscles compared
to gastrocnemii; furthermore, the
promoted angiogenesis may be due to
higher level of hypoxia received in ad-
ductors after femoral artery ligation
(Fig. 8.15).
As regarding the muscle regeneration,
not surprisingly we observed that satel-
lite cells were principally activated in ve-
hicle–injected muscle; this was particu-
larly true for adductors and less evident
in gastrocnemii. It seems like that af-
ter ischemia the hypoxia condition, the
reduced level of VEGF and the minor
perfusion induced tissue damages result-
ing in untreated muscle regeneration; fur-
thermore, adductors were more sensitive
to the proximal femoral artery ligation
than gastrocnemii (Fig. 8.16).
Figure 8.16. Skeletal muscle regeneration mediated by satellite cells activation.
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Role of vascular progenitor cells in Mo¨nckeberg
sclerosis
8.9 Femoral arteries collection,
classification and statistical
analysis
From January 2005 to March 2010 we
have collected a series of 111 human
femoral arteries from healthy multiorgan
donors ranging from 14 to 59 years old
(middle age 36,5 years); 70 were male
(63%) and 41 (37%) were female. On
the whole, the 25,2% of arteries pre-
sented calcification in the tunica media
(27% M and 32% F). Morphologically,
the calcified vessels preserved their phys-
iological structure, did not present in-
flammation elements (cells, endothelial
rearrangements, ecc), but only focal ore
more extended calcification especially in
tunica media and sometimes in the in-
ner elastic lamina containing osteoblasts,
osteoclasts, chondroclasts, condroblasts
(Fig. 8.17).
After the classification in calcified and
non calcified vessels, the donors were di-
vided in different sex and age classes:
10-19 years, 20-29 years, 30-39 years, 40-
49 years and 50-59 years, and in different
risk classes on the basis of own clinical
status. Successively we performed cor-
relation analysis and calculated the Odd
Ratio (OR) between these different cate-
gories (Tables 8.1 and 8.2).
Our results showed that Mo¨ncke-
berg sclerosis is more frequent in women
(OR= 1,70), in young people (20-29
years; OR= 1,35) and older subjects (50-
59 years; OR=1,97); furthermore, unlike
atherosclerosis, we did not found any cor-
relation between the presence of vascu-
lar calcification and diabetes, tabagism,
and hypercholesterolemia, whilst we have
noted a strong correlation with hyperten-
sion (OR= 1,68).
Figure 8.17. Hematoxylin and Eosin stain of calcified femoral artery.
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Table 8.1. Patients classifications on the basis of age and arterial calcification.
Age Calcified Non calcified
(year) (M:F) (M:F)
9-19 0 (0:0) 9 (6:3)
20-29 8 (4:4) 19 (13:6)
30-39 4 (3:1) 12 (10:2)
40-49 9 (5:4) 31 (18:13)
50-59 7 (3:4) 12 (8:3)
8.10 Isolation and flow cytometry
characterization of calcifying
cells
We succeded in isolation of VW-MSCs
from one calcified vessel which were
called cVW-MSCs. These cells were mor-
phologically and immunophenotypically
identical to the non calcified VW-MSCs
(ncVW-MSCs); the cells were spindle-
shaped and had a tendency to grow in a
whorled pattern. cVW-MSCs population
expressed typical mesenchymal antigens
Table 8.2. Patients classifications on the basis of risk factors and arterial calcification.
Risk Factors Calcified Non calcified
(M:F) (M:F)
Diabets 0 4 (2:2)
Tabagism 7 (3:4) 28 (18:10)
Hypertension 2 (1:1) 4 (4:0)
Hypercolesterolemia 0 5 (3:2)
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Figure 8.18. Flow cytometry of calcified VW-MSCs.
such as, CD44, CD105, CD90, CD29 and
CD166; on the contrary hematopoietic
(CD45) and endothelial (CD34) lineage
markers were negative, whereas stemness
markers, i.e., Sca-1, Oct-4, Notch-1 and
Stro-1, were more intense (Fig. 8.18).
8.11 Osteogenic assay
At passage 3, cVW-MSCs were induced
to osteogenic lineage; the differentiation
was evaluated by von Kossa staining and
ultrastructural analysis. Conversely to
the ncVW-MSC, the osteogenic differen-
tiation potential was very efficient; von
Kossa staining revealed numerous and
diffuse calcium deposits highlighted as
brown spots in the Fig. 8.19.
The analysis in TEM showed that
induced cells were able to produce ma-
ture osteoid matrix, precursor of trabec-
ular bone, rich in ossification elements
ranging from hydroxiapatite crystals to
mature bone. Uninduced cells retain
their mesenchymal characteristics, whilst
ncVW-MSCs displayed a less intensive
and early commitment revealed only by
TEM and not by von Kossa staining
(compare Fig. 8.20 with Fig. 8.9).
8.12 Immunohistochemistry assay
and statistical analysis
The immunohistochemical analysis of
Osx positive cells on vascular tissue slides
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Figure 8.19. Von Kossa staining of c-VW-MSC. A) uninduced cells
and B) induced cells.
permitted us to evaluate a possible dif-
ferential distribution of osteoprogenitor
cells along tunica media and adventitia
and to quantify the cells in both tu-
nica and in samples collected from donors
with different clinical conditions. The
Osx+ cells principally consist in smooth
muscle cells and pericytes with rounded
and small nuclei; no endothelial cells re-
sulted positive to stain (Fig. 8.21).
We have manually counted nuclei and
calculated the percentage of nuclear pos-
itivity on the total number of nuclei and
successively we performed a statistical
analysis of our results and compared the
data obtained from samples of subject
affected or not by hypertension. As re-
ported in Fig. 8.22, we found that in cal-
cified group, the Osx levels are higher in
hypertension condition than in the
Figure 8.20. TEM analysis of osteogenic commitment of c-VW-MSC. A) unin-
duced cells and B) and C) induced cells.
83
8 – Results
Figure 8.21. In situ analysis of Osterix positive cells.
absence of risk factors (P<0,01); con-
versely, in non calcified group there are
not significant differences about Osx ex-
pression; these results are in line with
those obtained from correlation analysis
showing that in hypertension the vessels
are more prone to calcification.
Successively we evaluated the Osx
positivity separately both in tunica me-
dia and in tunica adventitia in order to
investigate the different localization of
calcifying cells. In calcified vessels of
subjects with no risk factors we did not
observe significant differences of Osx ex-
pression between the two tunica, though
there are more positive cells in the ad-
ventitia than in the media; conversely,
in hypertension we found higher levels of
Osx expression in the tunica media com-
pared to the adventitia. These results
Figure 8.22. Quantification analysis of Osx positive cells in femoral ar-
teries harvested from subjects affected by hypertension (Hyp +) or non
exposed to risk factors (Hyp -).
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Figure 8.23. Quantification analysis of Osx positive cells in tunica media and ad-
ventitia of femoral arteries harvested from subjects affected by hypertension (Hyp
+) or non exposed to risk factors (Hyp -).
support the hypothesis that vascular cal-
cifying cells reside in the adventitia and
in response to pro osteogenic stimuli mi-
grate toward the media where they dif-
ferentiate in osteoblasts and produce os-
teoid matrix. Not surprisingly, in non
calcified vessels and in both conditions
we found that Osx positive cells princi-
pally reside in the tunica adventitia; they
are potentially able to produce osteoid





Vessel wall progenitors are responsi-
ble for the tissue integrity and homeosta-
sis during postnatal life. Responses to
various stimuli and signals are synergic
and involve cells which reside within all
the vascular wall components. In the in-
tima, ECs function is strictly dependent
on the interaction with blood circulat-
ing cells which contain subsets of EPCs;
these progenitors help resident ECs in
lining repair. The interface between me-
dia and adventitia has vasculogenic prop-
erties and possibly a niche-like function
which could explain the existence of res-
ident MSCs in large and medium-sized
vessels. The media layer contains cells
of different embryological origin display-
ing heterogeneous properties in terms of
multipotency, migration and prolifera-
tion ability. Thus each subpopulation
may participate in tissue regeneration in
a different manner. Again, morphological
analysis reflects the same pattern of het-
erogeneity. Different vascular segments
display variability as disease progresses
and are susceptible to atherosclerosis and
inflammatory diseases in a different way.
Moreover, some vascular diseases arise in
specific vascular districts: examples in-
clude vasculitis, inflammatory aneurysms
and diabetic angiopathy. Aortic ho-
mograft transplantation in canine mod-
els co-validates this hypothesis: patterns
of disease progression are strongly influ-
enced by intrinsic differences in the arte-
rial wall cells and are not environment-
dependent; as a result hemodynamic
flow patterns, alone, cannot trigger the
development of atherosclerotic lesions
(Haimovici et al, 1964 and 1971).
Apart from progenitors, adult arter-
ies of animals and human may con-
tain cells with characteristics of ances-
tral stem cells. Clues supporting this hy-
pothesis come from studies on cells re-
covered from arterial segments. Exam-
ples include the presence of a “side pop-
ulation” at flow cytometry (Sainz et al,
2006), the expression of the Sca-1 stem-
ness molecule (Hu et al, 2004) and c-
kit receptor (Pasquinelli et al 2007 a),
the ability to form spheroid colonies “in
vitro” (Howson et al, 2005). However, a
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cell able to give rise to a complete hi-
erarchy of vascular progenitors still re-
mains to be isolated from the adult vas-
cular wall. Conceivably a model could be
proposed in which a cell type, normally
involved in physiological vascular home-
ostasis, might also act as a reservoir of
undifferentiated cells ready to supply the
cellular demands of the tissue they be-
long to, acquiring local phenotypic char-
acteristics, or to mobilize in the circulat-
ing blood in response to vascular injury
stimuli. MSCs would be good candidates
for supplying this reserve function. This
possibility is supported by a recent paper
by a Brazilian research group (da Silva
Meirelles et al, 2006). MSC populations
originating from brain, spleen, liver, kid-
ney glomeruli, lung, bone marrow, mus-
cle, thymus and pancreas present a sim-
ilar morphology and, to a certain ex-
tent, surface marker profile. However,
these cells differ in adipogenic and os-
teogenic potential, probably due to the
influence of the local microenvironment
from which they come. This may re-
flect the importance of the niche in es-
tablishing the phenotype of the stem cells
it interacts with. The wide distribution
of MSCs and their similar characteris-
tics suggests a closer relationship among
them. A few reports have hypothesized
that, at least in animal fetal tissues,
MSCs may derive from mesangioblast-
like perivascular cells; therefore it is con-
ceivable that tissue specific MSCs ac-
tually derive from the vasculature. To
test this hypothesis the authors studied
MSCs obtained from the aorta, the vena
cava and kidney glomerulus capillaries.
After comparing these populations with
the MSCs obtained from more conven-
tional sources, they concluded that the
MSC compartment extends throughout
the post-natal organism as a result of its
perivascular location. However their pre-
cise native localization remains obscure.
Recent observations identify the pericyte
as the MSC “in situ” counterpart (Crisan
et al, 2008). However, when the perivas-
cular microenvironment is studied in ul-
trastructural detail, two possible target
cell populations can be associated with
MSC potentialities: i) the pericyte, a my-
oid periendothelial cell which shares its
basal lamina with that of ECs; ii) the
perivascular fibroblasts originally identi-
fied by Joris and Majno as veiled cells
in the rat coronary artery (Joris et al,
1974). These cells lack any contrac-
tile filaments and are characterized by
the presence of elaborate long extremely
thin cytoplasmic processes. These differ-
ences could also explain why some MSC
cell populations express markers of the
pericyte lineage, e.g. NG2 and smooth
muscle actin, whereas others maintain a
more restricted mesenchymal phenotype.
Although the precise in vivo MSC at-
tribution remains to be established, it
is conceivable that in case of necessity
these cells may re-program giving rise
to committed progenitors that gradually
integrate into the specific tissues. This
model does not exclude the possible ex-
istence of other tissue-specific stem cells;
however it highlights that a portion of
apparent post-natal stem cell diversity
might be attributed to local MSCs be-
having as tissue-specific stem cells, and
not to a different MSC population (da
Silva Meirelles et al, 2006). Besides the
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vascular progenitors identification and in
situ localization, their potential role in
vascular wall homeostasis and disease is
becoming recognized.
The upshot is that identification and
characterization of the progenitors in-
volved in physiological homeostasis and
pathological vascular remodeling is an is-
sue of great interest, one that may im-
prove current knowledge of vascular dis-
eases and may provide useful strategies
that can be transferred to the fields of
repair or regenerative medicine and tis-
sue engineering as well.
In previous studies we furnished a
detailed description of the “vasculo-
genic zone” (Zengin et al, 2006) of hu-
man thoracic aortas and femoral arteries
(Pasquinelli et al, 2007 a and Pacilli et
al, 2009) and we have also already docu-
mented the angiogenic properties of tho-
racic aorta-derived MSCs (Pasquinelli et
al, 2007 a). On the basis of our and other
works we tried to elucidate stem cell fea-
tures and multipotent abilities of mul-
tidistrict VW-MSCs, extending our ob-
servations to the aortic arch and femoral
artery.
We therefore analyzed fresh elastic
and muscular arteries from healthy mul-
tiorgan donors from which cells with a
plastic-adherent growth and a fibroblast-
like morphology were obtained. These
cells had the typical antigen expression
pattern of culture-expanded MSCs; they
were positive for a mixture of stemness
(Stro-1, Notch-1, Oct-4) and mesenchy-
mal (CD44, CD90, CD105, CD73, CD29,
CD166) markers, and never expressed
hematopoietic or endothelial cell mark-
ers. Since VW-MSCs are recovered from
entire human arterial segments, we eval-
uated the expression of stemness markers
directly on tissue sections by immuno-
histochemistry. In agreement with the
niche-like function of the vasculogenic
zone here we found that Notch-1, Stro-
1, Sca-1 and Oct-4 positive cells are lo-
cated in this area. Postnatal perivascular
stem cells are believed to be descendant
of cells derived from the embryonic dor-
sal aorta called mesoangioblasts (Minasi
et al, 2002); the presence of Oct-4 pos-
itive cells in adult multidistrict vascular
segments reinforces this hypothesis.
However, phenotype characterization
is not per se sufficient to give to a
cell population the property of stemness;
thus we explored other features common
to all stem cells. It is well known that
the ABC transporters and breast can-
cer resistance protein (ABCG2/BCRP),
are highly expressed in a population of
primitive stem cells, the side popula-
tion. SP cells were originally discov-
ered in bone marrow by their capacity
to exclude rhodamine 123 and Hoechst
dye 33342; however, extensive research
also revealed their presence in other non
hematopoietic tissues(Huls et al, 2009).
Hoechst positive-SP cells have been also
found in healthy arteries of the media
of adult mice (Sainz et al, 2006). Here
we show that human VW-MSCs collected
from different vascular segments contain
a subset of ancestral cells with SP phe-
notype.
Furthermore, we seeded cells in low
attachment plates to establish whether
they were capable of suspension growth.
In these conditions, neural and cancer
stem cells prove able to form colonies
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and VW-MSCs did so efficiently. The
stemness of cells forming spheres was
confirmed by immunofluorescence and
molecular analysis while electron mi-
croscopy determined their undifferenti-
ated condition. Comparing immunoflu-
orescence analysis and RNA expression,
we observed that cell spheroids expressed
Notch-1, Stro-1, c-kit, and Oct-4; Notch-
1 was the most expressed gene, thus sug-
gesting a major role in regulating the
stemness and the undifferentiated status
of VW-MSCs. To explain the lower ex-
pression level of Oct-4, we hypothesized
that a subset of VW-MSCs had more
ancestral characteristics; this is conso-
nant with results provided by SP cells,
clonal and bell-shaped nuclei analysis.
As expected, TEM showed that VW-
MSCs are undifferentiated mesenchymal
cells. Intercellular junctions were rare
and always of the primitive type; primary
cilia were also present and probably in-
fluence the balance of stem and progen-
itor cell proliferation versus differentia-
tion (Dubreuil et al, 2007). One interest-
ing characteristic of more ancestral cells
is their clonogenic ability; accordingly,
the clonogenic potential of single VW-
MSCs was assessed in limited dilution
experiments and a percentage of 0.36%
cells displayed this ability. According to
recent reports (Kroschinsky et al, 2008;
Gostjeva et al, 2006), we investigated the
nuclear morphology of VW-MSCs as ad-
ditional evidence of stemness. Regard-
less of the vascular source, the 0.30 ±
0.05 % of VW-MSCs showed bell-shaped
nuclei. Taken together these results doc-
ument the stemness and embryonic-like
quality of VW-MSC populations.
MSCs are considered a subset of post-
natal perivascular stem cells deriving
from multipotent mesenchymal precur-
sors, i.e., mesoangioblasts, which are lo-
calized in the embryonic dorsal aorta
(Minasi et al, 2002). Also human
MSCs deriving from pulmonary artery
(Hoshino et al, 2008) and saphena vein
(Covas et al, 2005) are multipotent.
Consequently, the in vitro mesengenic
property of MSCs deriving from addi-
tional human vascular sources was inves-
tigated; VW-MSCs from different vas-
cular segments were able to commit to-
wards adipogenic, osteogenic, chondro-
genic and leiomyogenic lineages.
As for adipogenesis, we observed a
progressive increase in cytoplasmic lipid
vacuoles in all populations; however, the
extent of adipogenesis was higher in VW-
MSCs deriving from thoracic aortas and
femoral arteries than was observed in
assays performed on cells deriving from
aortic arches. Although we have no
explanation for this difference, we may
assume that it has a relationship with
the embryological origin of the ascend-
ing aorta which is under the control of
neuroectodermal progenitors (Pacilli et
al, 2009).
VW-MSCs exhibit a good propen-
sity for chondrogenic but less for os-
teogenic commitment. Markers of car-
tilaginous differentiation such as type
II collagen were detected with immuno-
histochemical and ultrastructural assays.
The results from von Kossa staining
suggested a failed commitment; how-
ever, TEM revealed an ossification cor-
responded to a stage preceding the for-
mation of the trabecular bone.
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After three weeks of induction VW-
MSCs did in fact synthesize an osteoid
matrix enriched with multiple hydroxiap-
atite crystals. Presumably, the exposure
time was not sufficient to promote VW-
MSCs to complete ossification because of
their low innate propensity for osteoge-
nesis. When stimulated with leiomyo-
genic media, VW-MSCs increased their
levels of ASMA and h-CALD transcripts
and proteins and showed de novo ex-
pression of CALP, all specific markers
of human smooth muscle cells. These
results were confirmed by TEM which
demonstrated contractile filaments in in-
duced VW-MSCs. The concomitant
presence of rough endoplasmic reticu-
lum and well-organized fibronexus al-
lowed us to categorize the differentiat-
ing cells as myofibroblasts. According to
Eyden (Eyden et al, 2009), electron mi-
croscopy detection of cell-to-matrix junc-
tions enables us to identify myofibrob-
lasts and to distinguigh them from other
ASMA-expressing cytotypes, including
pericytes. This observation suggests
that, in the vascular wall, myofibrob-
lasts derive not only from smooth mus-
cle cell-to-myofibroblast transition (Hinz
et al, 2007) but also from local resident
mesenchymal cells, VW-MSCs being the
possible source. This is consistent with
the concept that vascular smooth mus-
cle cells are phenotypically heterogeneous
(Hao et al, 2006), and that cells involved
in remodeling injured arteries apparently
include smooth muscle cells from the me-
dia as well as adventitial fibroblasts (Za-
lewski et al, 2002).
We confirmed stem cell properties
and proangiogenic ability of VW-MSCs
also in a immunodeficient murine model
of hindlimb ischemia. After femoral
artery ligation we intramuscularly in-
jected TA-MSCs or vehicle in adductors
of hischemic left limb; the right contro-
lateral muscles acted as internal control.
We chosed TA-MSCs because their an-
giogenic ability was well characterized in
in vitro recent study (Pasquinelli et al,
2007 a). Eco color Doppler analysis for
Blood Flow recovery showed that cellu-
lar administration did not significantly
accelerate blood flow recovery in treated
animals compared to control group; how-
ever, it induced a slight ameliorating limb
blood flow at 14 days in treated animals
compared to 7 days postischemia and to
vehicle-injected animals which showed a
decline in limb blood perfusion. As re-
garding foot perfusion both at 7 days
and 14 days after hind limb ischemia we
observed higher levels of blood flow in
VW-MSCs injected group compared to
untreated one. Although there were not
a significant recover of blood perfusion,
the analysis of adductors and gastrocne-
mii explanted post-mortem revealed an
important role of human vascular cells in
reducing critical ischemia consequences
such as limb amputation. In general, ad-
ductors were more sensitive to ischemia
and cell therapy compared to gastrocne-
mii; this is probably due to the fact that
femoral ligation was performed in prox-
imal region which irrorates this muscle.
Indeed, we found that capillary density
and VEGF level were higher in VW-
MSC-injected than in vehicle-injected
muscles and this differences were sta-
tistically significant. As results hypoxic
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conditions were attenuated by vascular
progenitor cells which are able to engraft
the preexistent vessels and to originate
new capillaries by differentiating into ma-
ture endothelial cells. Furthermore, un-
like treated muscles, the vehicle-injected
adductors were not able to adapt them-
selves to impaired oxygen flux; as con-
sequence, we observed an activation of
skeletal muscle stem cells called satellite
cells (Pax7 positive), in order to preserve
the architectural and functional integrity
of the tissue. In gastrocnemii we re-
ceived only moderate hypoxic conditions
and consequently we did not found ele-
vated level of VEGF or more abundant
capillaries in VW-MSCs injected muscles
than the vehicle injected muscles. How-
ever there was a reduction of hypoxia
in treated muscles compared to the un-
treated one presumably due to the vas-
cular progenitor contribute in neoangio-
genesis as documented by human CD34
evaluation; furthermore this adaptation
was sufficient for good tissue function
which did not require satellite cells acti-
vation.
Overall, these data suggest that VW-
MSCs have the capacity to incorporate
in the host tissue, to localize around
the capillaries as natural mural compo-
nents and to support muscle function
and perfusion. These results and those
from other studies (Invernici et al, 2007;
Campagnolo et al, 2010) permit us to
think about clinical perspective regard-
ing vascular progenitor uses; it is possible
to speculate that, in general, VW-MSCs
might have potential therapeutic appli-
cation in vascular pathologies such as di-
abetic retinopathy that are characterized
by dysfunction of perivascular support
cells (Hammes et al, 2002).
In summary, our studies confirms the
recent acquisition that the MSC com-
partment is more widely distributed than
previously thought; it further highlights
that MSCs are resident in arteries of
both elastic and muscular architecture.
Changes in the immunophenotype and
plasticity are presumably correlated to
the specific in vivo vascular location and
may also be a consequence of their em-
bryologic origin. This suggests that MSC
functional roles are at least partially or-
gan and tissue specific; this intrinsic and
innate characteristic could explain the
different behavior of vascular district in
terms of preferentially onset of vascular
pathologies.
The arterial wall, indeed, is one of the
most frequent location of pathological in-
sults in humans; the balance between in-
jury and repair is altered by acute and
chronic stresses, the atherosclerosis be-
ing the major disease of the arterial wall;
vasculitis, aneurysmal dilatation, dyspla-
sia and even neoplasms are additional ex-
amples of diseases that can affect irre-
versibly the arterial wall. Furthermore,
pathological arteries may develop hetero-
topic mesodermal tissues which are ap-
parently unrelated to the original com-
position of adult tissue; examples include
the presence of cartilaginous metaplasia
with endochondral ossification (Qiao et
al 2003); exuberance of fibroblastic spin-
dle cells and fat tissue in inflammatory
abdominal aortic aneurysms (Tang et al,
2005). The mechanisms determining the
development of arterial calcification, a
feature of the atherosclerotic fibro-calcific
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plaque, remain largely unexplored. Arte-
rial calcification can be seen in other con-
ditions such as idiopathic infantile arte-
rial calcification (Glatz et al, 2006), dial-
ysis (Ketteler et al, 2005) and diabetic
(Hayden et al, 2005) patients. The pre-
mature diagnosis of vascular calcification
is an issue of great interest since it can
be pursuit without clinical invasive tech-
niques and is useful to prevent cardiovas-
cular events; nevertheless, four forms of
vascular calcification exist and not all are
a consequence of a preexistent pathology
of vascular wall (Guzman et al, 2007).
Medial arterial calcification is also
called Mo¨nckeberg sclerosis and may be
found in conjunction with atherosclerotic
lesions or it may occur independently;
the latest assumption is not commonly
accepted, in fact many researchers re-
tain that Mo¨nckeberg sclerosis is only
the final step of the atherosclerotic pro-
cess and do not recognize its own iden-
tity (McCullough et al, 2008; Fuchs et
al, 1985); however, the experimental evi-
dences of an individual pathology are nu-
merous (Hirsch et al, 1993; Rumberger
et al, 1994; Proudfoot et al, 2001). Sev-
eral models have been proposed to ex-
plain the origin of vascular ossification
and postulated the active contribute of
pluripotent arterial cells named calcify-
ing vascular cells in response to vas-
cular stimuli. Another hypothesis as-
cribes the onset of vascular calcifica-
tion to an altered bioavailability of pro-
teins inhibiting precipitation, chelation
and sequester of ions. However, these
findings indicate that vascular calcifica-
tion is an active, regulated process un-
der the control of cells expressing genes
proper of osteoblasts; it seems likely that
proposed models are not mutually ex-
clusive and resident cells play a funda-
mental role in the pathological mecha-
nism (Doherty et al, 2004). To estab-
lish VW-MSCs contribute in Mo¨nckeberg
sclerosis onset, we studied a wide series
of healthy femoral artery segments col-
lected from January 2005 to march 2010
at Regional CardioVascular tissue bank
in Bologna; on these samples we evalu-
ated the frequency of Mo¨nckeberg sclero-
sis and investigated a possible correlation
with common atherosclerotic risk factors.
We recovered 111 samples from multior-
gan donors ranging from 14 to 59 years
old (middle age 36,5 years); 70 were male
(63%) and 41 (37%) were female. On
the whole, the 25,2% of arteries presented
calcification in the tunica media (27%
M and 32% F) and this phenomenon is
more frequent in women (OR= 1,70), in
young people (20-29 years; OR= 1,35)
and older subjects (50-59 years; OR=
1,97); this findings well fit with those
reported by other groups in which were
demonstrated that estrogen could pro-
mote vascular calcification increasing cal-
cified nodule formation and augmenting
the expression of osteogenic markers and
that vascular ossification starts during
the second and third decade of life (Hirsh
et al, 1993; Rumberger et al., 1994). Al-
though diabetes, tabagism and hyperc-
holesterolemia promote vascular osteoge-
nesis and play an important role in trans-
forming vascular cells into osteoblast-like
cells (Aronson et a, 2002; Kilaru et al,
2001) we did not find any correlation be-
tween the onset of Mo¨nckeberg sclerosis
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and these risk factors. However, un un-
expected results was that the pathology
is related with hypertension (OR= 1,68).
Actually we are not able to demonstrate
if the hypertension is a cause or a conse-
quence of vascular rigidity; more exper-
iments have to be performed to explain
it. These findings support the hypothe-
sis that Mo¨nckeberg sclerosis is more fre-
quent than previously thought; further-
more, the vascular ossification is asymp-
tomatic, affects young people and is un-
related to typical aspects of atheroscle-
rosis; we did not find inflammatory cells,
lipid core, foam cells, but only bone ele-
ments like osteoblasts, osteoclasts, chon-
droclasts, condroblasts and sometimes
architecturally complete trabecular bone;
moreover, the calcifications occur in sub-
jects with normal calcium and phospho-
rous levels and this distinguishes it from
calciphylaxis. Spontaneous bone forma-
tion is difficult to explain if we did not
refer to a direct involvement of vascu-
lar cells. We have already found that
VW-MSCs isolated from healthy vascular
segments are able to differentiate in adi-
pogenic, chondrogenic and leiomyogenic
lineages but are less prone to osteogenesis
(Pasquinelli et al, 2010); since resident
progenitor cells can also be recovered
from calcified femoral arteries and they
are probably the major players in spon-
taneous calcifications, we tested their os-
teogenic ability. VW-MSCs derived from
calcified vessels (cVW-MSCs) exhibit the
same immunophenotype of cells derived
from non calcified counterpart (ncVW-
MSCs) but showed a strong predisposi-
tion in in vitro osteogenesis as demon-
strated by von Kossa staining and TEM
analysis; moreover, as Calcified Vascu-
lar Cells (CVCs) described by Demer’s
group in the aorta (Tintut et al, 2003),
femoral artery derived cVW-MSCs ex-
press Stro-1 and Sca-1, two markers of
multipotent cells able to differentiate in
mineralizing osteoblasts. Successively,
we investigated the in situ location of os-
teoprogenitor cells evaluating the expres-
sion of Osterix (Osx), a note master gene
essential for differentiation of mesenchy-
mal progenitors into terminally differen-
tiated osteoblasts, on tissue sections of
calcified and non calcified femoral artery.
Complessively, we found that in calcified
group, the Osx levels are higher in hy-
pertension condition than in the absence
of risk factors (P<0,01); conversely, in
non calcified group there are not signif-
icant differences about Osx expression;
these results are in line with those ob-
tained from correlation analysis showing
that in hypertension the vessels are more
prone to calcification. Successively, we
performed analysis in order to appreci-
ate different distribution of Osx+ cells
between tunica media and tunica adven-
titia and to compare the vessels collected
from subjects without exposition to risk
factors and subject affected by hyperten-
sion. Some researchers retain that os-
teoprogenitor cells are contiguous to the
vasa vasorum where they are inactive;
further to osteogenic physiological stim-
uli the cells migrate to the tunica media
and start to produce bone matrix (Esner
et al, 2006). According to this hypoth-
esis, we found that in calcified vessels of
subjects with no risk factors we did not
observe significant differences of Osx
expression between the two tunica,
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though there are more positive cells in
the adventitia than in the media; con-
versely, in hypertension we found higher
levels of Osx expression in the tunica me-
dia compared to the adventitia. Prob-
ably, the hemodynamic flux in hyper-
tension condition actives numerous os-
teoprogenitor cells normally resident in
adventitia that migrate in the tunica
media where they start to produce os-
teoid matrix. Furthermore, in vitro
osteogenesis assay performed on cVW-
MSCs and ncVW-MSCs showed that in-
duced ncVW-MSCs express higher level
of Osx compared to cVW-MSCs; unin-
duced cells do not express this osteogenic
factor; thus, Osx is a key factor in regu-
lating vascular ossification and probably
it is switched off in mature cells. On
the basis of our results we cannot es-
tablish if hypertension is a cause or a
consequence of vascular calcification, but
we demonstrate unequivocally that the
Mo¨nckeberg sclerosis has an independent
origin from atherosclerosis and presents
peculiar aspects respect to other vascular
diseases. The ectopic formation of bone
tissue is an active and strictly regulated
process in which VW-MSCs are directly
involved and Osx is an early activator.
On the basis of our results, we re-
tain that the feasibility of isolating MSCs
from arterial samples collected from mul-
tiorgan donors in qualified tissue bank fa-
cilities and of storing them in good cell
and tissue practice-certified cell factories
could prompt use of them in cardiovascu-
lar research and clinical applications. In-
deed, VW-MSCs can be considered the
natural candidate for the realization of
biosynthetic arterial substitutes and for
cell therapy, especially in the case of vas-
cular diseases where conventional treat-
ments fail. Future studies establishing
the in vivo regenerative and repair po-
tential of VW-MSC in animal models of
vascular diseases will no doubt seek an-
swers to this still unexplored field.
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